| Rx0000077 |
AbbVie |
03/31/2021 |
00074081702 |
(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074006702 |
(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PK |
01/01/2021 |
616.83 |
8952.31 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074061602 |
(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074937402 |
(adalimumab) HUMIRA 20MG/0.4ML (2 SYRINGES) |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074433902 |
(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS) |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074379902 |
(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES) |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074254003 |
(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACK |
01/01/2021 |
1233.65 |
17904.62 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074012403 |
(adalimumab) HUMIRA 80MG,0.8mL 3 Pens |
01/01/2021 |
1233.65 |
17904.62 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074153903 |
(adalimumab) HUMIRA KIT 80MG/0.8ML, 40MG/0.4ML 3 PENS |
01/01/2021 |
822.44 |
11936.40 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074055402 |
(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074024302 |
(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074433906 |
(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS) |
01/01/2021 |
1233.65 |
17904.62 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074433907 |
(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS) |
01/01/2021 |
822.44 |
11936.40 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074634702 |
(adalimumab) Humira, Single Dose Syringe, 10 mg/0.2mL |
01/01/2021 |
411.21 |
5968.18 |
11/14/2034 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074347303 |
(leuprolide acetate) LUPRON 45MG 6MTH |
01/01/2021 |
619.12 |
10604.85 |
02/05/2031 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074244003 |
(leuprolide acetate) Lupron Depot Ped, 15 mg PDS Kit |
01/01/2021 |
208.29 |
3567.80 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074377903 |
(leuprolide acetate) LUPRON DEPOT PED, 3month, 11.25mg |
01/01/2021 |
567.34 |
9718.03 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074969403 |
(leuprolide acetate) LUPRON DEPOT PED, 3month, 30mg |
01/01/2021 |
624.87 |
10703.43 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074210803 |
(leuprolide acetate) Lupron Depot Ped, 7.5 mg PDS Kit |
01/01/2021 |
104.17 |
1784.28 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074366303 |
(leuprolide acetate) Lupron Depot, 3 Month 11.25 mg PDS Kit |
01/01/2021 |
259.77 |
4449.61 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074334603 |
(leuprolide acetate) Lupron Depot, 3 Month 22.5 mg PDS Kit |
01/01/2021 |
309.55 |
5302.34 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074364103 |
(leuprolide acetate) Lupron Depot, 3.75 mg PDS Kit |
01/01/2021 |
86.59 |
1483.19 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074368303 |
(leuprolide acetate) Lupron Depot, 4 Month 30 mg PDS Kit |
01/01/2021 |
412.74 |
7069.80 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074364203 |
(leuprolide acetate) Lupron Depot, 7.5 mg PDS Kit |
01/01/2021 |
103.18 |
1767.45 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074228203 |
(leuprolide acetate) Lupron Depot-Ped 11.25 mg PDS Kit |
01/01/2021 |
189.11 |
3239.33 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074105305 |
(leuprolide acetate/norethindrone acetate) Lupaneta 11.25 mg (3 Month) Kit |
01/01/2021 |
259.77 |
4449.61 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00074105205 |
(leuprolide acetate/norethindrone acetate) Lupaneta, 3.75 mg (1 Month) Kit |
01/01/2021 |
86.59 |
1483.19 |
None |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032121201 |
(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP |
01/01/2021 |
20.71 |
354.73 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032121207 |
(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP |
01/01/2021 |
51.78 |
886.81 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032122401 |
(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP |
01/01/2021 |
41.05 |
703.13 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032122407 |
(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP |
01/01/2021 |
100.96 |
1729.52 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032120370 |
(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP |
01/01/2021 |
6.13 |
104.93 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032301613 |
(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP |
01/01/2021 |
62.33 |
1067.62 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032301628 |
(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP |
01/01/2021 |
155.80 |
2668.74 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032120601 |
(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP |
01/01/2021 |
10.37 |
177.47 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000077 |
AbbVie |
03/31/2021 |
00032120607 |
(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP |
01/01/2021 |
25.91 |
443.71 |
02/07/2030 |
Single Source Drug |
None |
1 |
AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
09/30/2021 |
63090010030 |
NUPLAZID, 10mg, Oral Tablet, 30 tablets |
07/10/2021 |
342.00 |
3980.00 |
03/23/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000018 |
ACADIA Pharmaceuticals Inc. |
09/30/2021 |
63090034030 |
NUPLAZID, 34 mg, Oral Capsule, 30 capsules |
07/10/2021 |
342.00 |
3980.00 |
08/27/2038 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000278 |
Acella Pharamceuticals, LLC |
09/30/2021 |
42192060840 |
Gabapentin 300mg/ 6ml Unit dose Lq 40ct |
07/01/2021 |
40.00 |
125.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years. |
| Rx0000021 |
Acorda Therapeutics, Inc. |
03/31/2021 |
10144042760 |
AMPYRA (dalfampridine) Extended Release Tablets 10mg 60 Tablet Bottles |
01/01/2021 |
278.75 |
3212.89 |
None |
Innovator Multiple Source Drug |
None |
1 |
AMPYRA® is the company’s primary source of revenue while working to make this product and its Parkinson’s product available to patients |
None |
AMPYRA® has not been reformulated, but is the company’s primary source of revenue while working to make this product and its Parkinson’s product available to patients |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are no patents listed in the Orange book for Ampyra. Ampyra became subject to competition from generic versions of Ampyra starting in late 2018 as a result of an adverse U.S. federal district court ruling that invalidated certain Ampyra Orange book-listed patents. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215050115 |
OPSUMIT® (macitentan) Strength: 10 mg Package Size:15 Form: Tablet |
01/15/2021 |
242.10 |
5285.85 |
04/18/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215050130 |
OPSUMIT® (macitentan) Strength: 10 mg Package Size:30 Form: Tablet |
01/15/2021 |
484.21 |
10571.70 |
04/18/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215061006 |
UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215061206 |
UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215061406 |
UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215061606 |
UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215060214 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet |
01/15/2021 |
1321.95 |
28862.61 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215060206 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet |
01/15/2021 |
566.55 |
12369.69 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215062820 |
UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet |
01/15/2021 |
1321.94 |
28862.38 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215060406 |
UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215060606 |
UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000251 |
Actelion Pharmaceuticals US, Inc |
03/31/2021 |
66215060806 |
UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet |
01/15/2021 |
881.08 |
19236.90 |
12/01/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2021 |
76431011001 |
JUXTAPID 10 MG CAPS, bottle of 28 capsules |
02/01/2021 |
1788.59 |
46502.12 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2021 |
76431012001 |
JUXTAPID 20 MG CAPS, bottle of 28 capsules |
02/01/2021 |
1788.59 |
46502.12 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2021 |
76431013001 |
JUXTAPID 30 MG CAPS, bottle of 28 capsules |
02/01/2021 |
1788.59 |
46502.12 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2021 |
76431010501 |
JUXTAPID 5 MG CAPS - bottle of 28 |
02/01/2021 |
1788.59 |
46502.12 |
08/19/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000203 |
Aegerion Pharmaceuticals, Inc. |
03/31/2021 |
76431021001 |
MYALEPT 11.3MG VIAL |
02/01/2021 |
203.73 |
5297.05 |
12/31/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/12/2015 |
Astra Zeneca |
325000000 |
None |
None |
3493.00 |
None |
2014 |
3493.00 |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
17478030703 |
Azasite 1% Opth Soln 10mg, 2.5mL, 1 Bottle |
12/30/2021 |
16.50 |
222.71 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
76478000105 |
Betimol 0.25% Opth Solution 2.56mg/mL, 5mL, 1 Bottle |
12/30/2021 |
10.22 |
137.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
76478000215 |
Betimol 0.5% Opth Solution 5.12mg/mL, 15mL, 1 Bottle |
12/30/2021 |
32.63 |
440.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
76478000205 |
Betimol 0.5% Opth Solution 5.12mg/mL, 5mL, 1 Bottle |
12/30/2021 |
11.29 |
152.36 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
76478000210 |
Betimol 0.50% Opth Solution 5.12mg/mL, 10mL, 1 Bottle |
12/30/2021 |
21.68 |
292.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000085 |
Akorn Inc |
12/31/2021 |
17478060930 |
Zioptan Ophth Sol .0015% .3mL/.0045mg, .3mL-30 UD pk |
12/30/2021 |
17.04 |
230.05 |
05/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023320503 |
(bimatoprost) LUMIGAN 0.01% EYE DROPS 2.5 mL |
01/01/2021 |
10.34 |
217.16 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023320505 |
(bimatoprost) LUMIGAN 0.01% EYE DROPS 5 mL |
01/01/2021 |
20.67 |
434.14 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023320508 |
(bimatoprost) LUMIGAN 0.01% EYE DROPS 7.5 mL |
01/01/2021 |
31.01 |
651.18 |
06/13/2027 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023932110 |
(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 10 mL |
01/01/2021 |
16.79 |
352.56 |
03/02/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023932115 |
(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 15 mL |
01/01/2021 |
25.19 |
528.92 |
03/02/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023932105 |
(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 5 mL |
01/01/2021 |
8.40 |
176.36 |
03/02/2024 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023917710 |
(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 10 mL |
01/01/2021 |
17.90 |
375.94 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023917715 |
(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 15 mL |
01/01/2021 |
26.86 |
563.97 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023917705 |
(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 5 mL |
01/01/2021 |
8.95 |
188.02 |
01/28/2022 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023921110 |
(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 10 mL |
01/01/2021 |
18.52 |
388.83 |
04/19/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023921115 |
(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 15 mL |
01/01/2021 |
27.77 |
583.20 |
04/19/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023921105 |
(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 5 mL |
01/01/2021 |
9.26 |
194.41 |
04/19/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456040010 |
(ceftaroline fosamil acetate) TEFLARO 400 MG VIAL 10 |
01/01/2021 |
100.86 |
2118.13 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456040001 |
(ceftaroline fosamil acetate) TEFLARO 400 MG VIAL 1-Inner Pack |
01/01/2021 |
10.09 |
211.81 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456060010 |
(ceftaroline fosamil acetate) TEFLARO 600 MG VIAL 10 |
01/01/2021 |
100.86 |
2118.13 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456060001 |
(ceftaroline fosamil acetate) TEFLARO 600 MG VIAL 1-Inner Pack |
01/01/2021 |
10.09 |
211.81 |
02/10/2031 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023916330 |
(cyclosporine) RESTASIS 0.05% EYE EMULSION 30 |
01/01/2021 |
14.64 |
307.43 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023916360 |
(cyclosporine) RESTASIS 0.05% EYE EMULSION 60 |
01/01/2021 |
29.28 |
614.89 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023530105 |
(cyclosporine) RESTASIS MULTIDOSE 0.05% EYE 5.5 mL |
01/01/2021 |
29.28 |
614.89 |
05/11/2034 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
61874010060 |
(eluxadoline) VIBERZI 100 MG TABLET 60 |
01/01/2021 |
65.87 |
1383.26 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
61874007560 |
(eluxadoline) VIBERZI 75 MG TABLET 60 |
01/01/2021 |
65.87 |
1383.26 |
03/14/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456201001 |
(escitalopram oxalate) LEXAPRO 10 MG TABLET 100 |
01/01/2021 |
60.24 |
1264.96 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456202001 |
(escitalopram oxalate) LEXAPRO 20 MG TABLET 100 |
01/01/2021 |
62.86 |
1319.99 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456200501 |
(escitalopram oxalate) LEXAPRO 5 MG TABLET 100 |
01/01/2021 |
57.61 |
1209.86 |
02/12/2023 |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456220228 |
(levomilnacipran HCl) FETZIMA 20-40 MG TITRATION PAK 1 EA |
01/01/2021 |
19.25 |
404.20 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456221230 |
(levomilnacipran HCl) FETZIMA ER 120 MG CAPSULE 30 |
01/01/2021 |
20.62 |
433.06 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456222030 |
(levomilnacipran HCl) FETZIMA ER 20 MG CAPSULE 30 |
01/01/2021 |
20.62 |
433.06 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456224030 |
(levomilnacipran HCl) FETZIMA ER 40 MG CAPSULE 30 |
01/01/2021 |
20.62 |
433.06 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456228030 |
(levomilnacipran HCl) FETZIMA ER 80 MG CAPSULE 30 |
01/01/2021 |
20.62 |
433.06 |
05/23/2032 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023585801 |
(levonorgestrel) LILETTA 52 MG SYSTEM 1 |
01/01/2021 |
58.23 |
845.10 |
03/22/2034 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456120130 |
(linaclotide) LINZESS 145 MCG CAPSULE 30 |
01/01/2021 |
22.25 |
467.27 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456120230 |
(linaclotide) LINZESS 290 MCG CAPSULE 30 |
01/01/2021 |
22.25 |
467.27 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456120330 |
(linaclotide) LINZESS 72 MCG CAPSULE 30 |
01/01/2021 |
22.25 |
467.27 |
08/16/2033 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456121430 |
(memantine HCl/donepezil HCl) NAMZARIC 14 MG-10 MG CAPSULE 30 |
01/01/2021 |
24.29 |
510.08 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456122130 |
(memantine HCl/donepezil HCl) NAMZARIC 21 MG-10 MG CAPSULE 30 |
01/01/2021 |
24.29 |
510.08 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456122830 |
(memantine HCl/donepezil HCl) NAMZARIC 28 MG-10 MG CAPSULE 30 |
01/01/2021 |
24.29 |
510.08 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456120730 |
(memantine HCl/donepezil HCl) NAMZARIC 7 MG-10 MG CAPSULE 30 |
01/01/2021 |
24.29 |
510.08 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456122929 |
(memantine HCl/donepezil HCl) NAMZARIC TITRATION PACK 1 EA |
01/01/2021 |
22.67 |
476.07 |
12/05/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456151060 |
(milnacipran HCl) SAVELLA 100 MG TABLET 60 |
01/01/2021 |
20.05 |
421.08 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456151260 |
(milnacipran HCl) SAVELLA 12.5 MG TABLET 60 |
01/01/2021 |
20.05 |
421.08 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456152560 |
(milnacipran HCl) SAVELLA 25 MG TABLET 60 |
01/01/2021 |
20.05 |
421.08 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456155060 |
(milnacipran HCl) SAVELLA 50 MG TABLET 60 |
01/01/2021 |
20.05 |
421.08 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456150055 |
(milnacipran HCl) SAVELLA TITRATION PACK 1 EA |
01/01/2021 |
18.38 |
385.99 |
09/19/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456141030 |
(nebivolol HCl) BYSTOLIC 10 MG TABLET 30 |
01/01/2021 |
7.52 |
157.92 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456141090 |
(nebivolol HCl) BYSTOLIC 10 MG TABLET 90 |
01/01/2021 |
22.56 |
473.76 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456140263 |
(nebivolol HCl) BYSTOLIC 2.5 MG TABLET 10 X 10 UD |
01/01/2021 |
25.54 |
536.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456140230 |
(nebivolol HCl) BYSTOLIC 2.5 MG TABLET 30 |
01/01/2021 |
7.52 |
157.92 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456142030 |
(nebivolol HCl) BYSTOLIC 20 MG TABLET 30 |
01/01/2021 |
7.52 |
157.92 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456142090 |
(nebivolol HCl) BYSTOLIC 20 MG TABLET 90 |
01/01/2021 |
22.56 |
473.76 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456140563 |
(nebivolol HCl) BYSTOLIC 5 MG TABLET 10 X 10 UD |
01/01/2021 |
25.54 |
536.40 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456140530 |
(nebivolol HCl) BYSTOLIC 5 MG TABLET 30 |
01/01/2021 |
7.52 |
157.92 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456140590 |
(nebivolol HCl) BYSTOLIC 5 MG TABLET 90 |
01/01/2021 |
22.56 |
473.76 |
12/17/2021 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00430042014 |
(norethindrone acetate-ethinyl estradiol/ferrous fumarate) LO LOESTRIN FE 1-10 TABLET 5 x 28 |
01/01/2021 |
36.94 |
775.71 |
02/02/2029 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00023586230 |
(norethindrone acetate-ethinyl estradiol/ferrous fumarate) TAYTULLA 1 MG-20 MCG CAPSULE 5x28 |
01/01/2021 |
49.07 |
1030.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
58914017110 |
(sucralfate) CARAFATE 1 GM TABLET 100 |
01/01/2021 |
20.40 |
428.34 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
58914017014 |
(sucralfate) CARAFATE 1 GM/10 ML SUSP 14 fl. oz. |
01/01/2021 |
10.99 |
230.73 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456046101 |
(thyroid,pork) ARMOUR THYROID 120 MG TABLET 100 |
01/01/2021 |
8.07 |
169.37 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456045701 |
(thyroid,pork) ARMOUR THYROID 15 MG TABLET 100 |
01/01/2021 |
3.37 |
70.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456046201 |
(thyroid,pork) ARMOUR THYROID 180 MG TABLET 100 |
01/01/2021 |
6.04 |
126.77 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456046301 |
(thyroid,pork) ARMOUR THYROID 240 MG TABLET 100 |
01/01/2021 |
7.33 |
153.92 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456045801 |
(thyroid,pork) ARMOUR THYROID 30 MG TABLET 100 |
01/01/2021 |
3.96 |
83.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456046401 |
(thyroid,pork) ARMOUR THYROID 300 MG TABLET 100 |
01/01/2021 |
8.62 |
181.08 |
None |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456045901 |
(thyroid,pork) ARMOUR THYROID 60 MG TABLET 100 |
01/01/2021 |
4.40 |
92.38 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456046001 |
(thyroid,pork) ARMOUR THYROID 90 MG TABLET 100 |
01/01/2021 |
6.89 |
144.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456111030 |
(vilazodone HCl) VIIBRYD 10 MG TABLET 30 |
01/01/2021 |
14.29 |
300.14 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456110130 |
(vilazodone HCl) VIIBRYD 10-20 MG STARTER PACK 1 EA |
01/01/2021 |
14.29 |
300.14 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456112030 |
(vilazodone HCl) VIIBRYD 20 MG TABLET 30 |
01/01/2021 |
14.29 |
300.14 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000020 |
Allergan |
03/31/2021 |
00456114030 |
(vilazodone HCl) VIIBRYD 40 MG TABLET 30 |
01/01/2021 |
14.29 |
300.14 |
12/05/2022 |
Single Source Drug |
None |
1 |
AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110050201 |
Acticlate Oral Tablet 150 MG 60 tablet |
01/02/2021 |
66.14 |
2270.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110050101 |
Acticlate Oral Tablet 75 MG 60 tablet |
01/02/2021 |
66.14 |
2270.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110036760 |
Aczone 5% Gel 60g US |
01/02/2021 |
20.62 |
708.05 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/21/2018 |
Allergan |
None |
1 |
None |
593.63 |
542.13 |
2014 |
397.62 |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110036790 |
Aczone 5% Gel 90g US |
01/02/2021 |
27.05 |
928.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/21/2018 |
Allergan |
None |
1 |
None |
778.65 |
771.10 |
2014 |
569.12 |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110052660 |
Aczone 7,5% Gel 60g US |
01/02/2021 |
20.62 |
708.04 |
11/18/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/21/2018 |
Allergan |
None |
1 |
None |
593.63 |
542.13 |
2014 |
397.62 |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110052690 |
Aczone 7,5% Gel 90g US |
01/02/2021 |
27.05 |
928.73 |
11/18/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/21/2018 |
Allergan |
None |
1 |
None |
778.65 |
771.10 |
2014 |
569.12 |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110051815 |
Altabax 1% Ointment 15 g US |
01/02/2021 |
9.45 |
324.48 |
02/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110051830 |
Altabax 1% Ointment 30 g US |
01/02/2021 |
18.14 |
622.81 |
02/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110003412 |
Cordran Cream 0,025% 120 g US |
01/02/2021 |
14.62 |
501.82 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110003512 |
Cordran Cream 0,05% 120 g US |
01/02/2021 |
36.72 |
1260.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110005212 |
Cordran Lotion 0,05% 120 ml US |
01/02/2021 |
36.72 |
1260.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110002660 |
Cordran Ointment 0,05% 60 g US |
01/02/2021 |
22.16 |
760.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110081230 |
Fluoroplex Cream 1% 30g US |
01/02/2021 |
27.03 |
927.95 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110007130 |
Veltin Gel 1.2%/0.025% tube 30 g US |
01/02/2021 |
13.88 |
476.62 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110007160 |
Veltin Gel 1.2%/0.025% tube 60 g US |
01/02/2021 |
26.14 |
897.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110011100 |
Verdeso Foam 0,05% 100g Aerosol |
01/02/2021 |
29.77 |
1022.18 |
08/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000201 |
Almirall LLC |
03/31/2021 |
16110008045 |
Xolegel Gel 2% 45 g US |
01/02/2021 |
23.59 |
809.87 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
09/30/2021 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme 510mg (1 vial package size, injectable solution) |
07/01/2021 |
34.77 |
1193.62 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in new indications. We do not maintain records demonstrating how these and other costs are taken into consideration in making particular pricing decisions. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia.
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2021 |
59338077501 |
ferumoxytol 510MG/17 mL Feraheme 510mg Each |
01/01/2021 |
44.57 |
1158.85 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000037 |
AMAG Pharmaceuticals, Inc. |
03/31/2021 |
59338077510 |
ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10 |
01/01/2021 |
445.70 |
11588.50 |
06/30/2023 |
Single Source Drug |
None |
1 |
Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_
As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_
The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_
Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_
In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_
We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_ |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Feraheme was developed by AMAG and not subject to acquisition reporting |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2021 |
52937000120 |
Vascepa(Icosapent ethyl) 120 1g |
12/29/2021 |
10.33 |
354.55 |
06/28/2033 |
Single Source Drug |
4470446 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000050 |
Amarin Pharma, Inc. |
12/31/2021 |
52937000340 |
Vascepa(Icosapent ethyl) 240 500mg |
12/29/2021 |
12.08 |
414.81 |
06/28/2033 |
Single Source Drug |
4475 |
None |
Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study.
• The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold.
• On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA
• as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and
o Established cardiovascular disease, or
o Diabetes and two or more additional risk factors for cardiovascular disease
The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy.
Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5
1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019.
Accessed March 28, 2019.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455.
4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687.
5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014.
6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019.
7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000231 |
American Health Packaging |
06/30/2021 |
60687012125 |
ACAMPROSATE CAL 333 MG DR TAB 30 UD |
06/01/2021 |
8.84 |
67.81 |
None |
Non-innovator Multiple Source Drug |
14332 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2021 |
60687034501 |
CALCITRIOL CAPSULE 0.25MCG 100UD |
12/10/2021 |
9.90 |
73.78 |
None |
Non-innovator Multiple Source Drug |
5083 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=564 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
06/30/2021 |
60687054401 |
CLONAZEPAM 0.5 MG TAB 100 (10X10) UD |
06/01/2021 |
35.32 |
59.00 |
None |
Non-innovator Multiple Source Drug |
18945 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
06/30/2021 |
60687055501 |
CLONAZEPAM 1 MG TAB 100 (10X10) UD |
06/01/2021 |
35.32 |
59.00 |
None |
Non-innovator Multiple Source Drug |
13481 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2021 |
68084092125 |
CYCLOSPORINE CAPSULE 100MG 30UD |
11/26/2021 |
32.09 |
377.09 |
None |
Non-innovator Multiple Source Drug |
420 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=568 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2021 |
68084087925 |
CYCLOSPORINE CAPSULE 25MG 30UD |
11/26/2021 |
9.83 |
126.83 |
None |
Non-innovator Multiple Source Drug |
594 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=567 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2021 |
68001026632 |
FLUOROURACIL INJECTION 5G/100ML(50MG/ML) |
12/08/2021 |
0.03 |
51.40 |
None |
Non-innovator Multiple Source Drug |
12585 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=565 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
03/31/2021 |
60687060201 |
GABAPENTIN CAPS 400MG 100UD |
02/05/2021 |
2.91 |
19.38 |
None |
Non-innovator Multiple Source Drug |
9276 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=541 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000231 |
American Health Packaging |
12/31/2021 |
68084020201 |
PRIMIDONE TABLET 50MG 100UD |
11/26/2021 |
26.87 |
81.25 |
None |
Non-innovator Multiple Source Drug |
2832 |
None |
Market Conditions |
None |
No Change Improvement in the drug product |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=566 |
The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable". |
| Rx0000128 |
American Regent |
09/30/2021 |
00517250210 |
Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk |
09/30/2021 |
20.60 |
230.90 |
None |
Non-innovator Multiple Source Drug |
7315 |
None |
American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3037/dsi_sobc-final_102020.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000128 |
American Regent |
03/31/2021 |
00517065001 |
Injectafer Intravenous Solution 750 MG/15ML |
01/01/2021 |
34.19 |
1173.86 |
02/15/2028 |
Single Source Drug |
675579 |
None |
American Regent’s US Standards of Business Conduct (available at https://www.americanregent.com/media/2747/us-sobc-112019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
Not Applicabel |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Injectafer is not an acquired product. American Regent is the NDA holder of this NDC. |
| Rx0000128 |
American Regent |
12/31/2021 |
00517065001 |
Injectafer Intravenous Solution 750 MG/15ML |
10/01/2021 |
35.22 |
1209.08 |
02/15/2028 |
Single Source Drug |
760580 |
None |
American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3037/dsi_sobc-final_102020.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Injectafer is not an acquired product. American Regent is the NDA holder of this NDC. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406004401 |
Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406045601 |
Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pk |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406004404 |
Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406045604 |
Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pk |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406003201 |
Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406044501 |
Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406003204 |
Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406044504 |
Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406042534 |
Enbrel, 25mg (1 mL), Vial (EA), 4 pk |
01/22/2021 |
205.61 |
2984.08 |
04/24/2029 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406042541 |
Enbrel, 25mg (1mL), Vial (EA), 1 pk |
01/22/2021 |
51.40 |
746.02 |
04/24/2029 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406001001 |
Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack |
01/22/2021 |
51.40 |
746.02 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406001004 |
Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack |
01/22/2021 |
205.61 |
2984.08 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406005501 |
Enbrel, 25mg/0.5mL, Vial (EA), 1 pack |
01/22/2021 |
51.40 |
746.02 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406005504 |
Enbrel, 25mg/0.5mL, Vial (EA), 4 pack |
01/22/2021 |
205.61 |
2984.08 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406045501 |
Enbrel, 25mg/mL, Syringe (ML), 1 pk |
01/22/2021 |
51.40 |
746.02 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406045504 |
Enbrel, 25mg/mL, Syringe (ML), 4 pk |
01/22/2021 |
205.61 |
2984.08 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406002101 |
Enbrel, 50mg/mL, Syringe (ML), 1 pack |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406043501 |
Enbrel, 50mg/mL, Syringe (ML), 1 pk |
01/22/2021 |
102.80 |
1492.04 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406002104 |
Enbrel, 50mg/mL, Syringe (ML), 4 pack |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
58406043504 |
Enbrel, 50mg/mL, Syringe (ML), 4 pk |
01/22/2021 |
411.22 |
5968.16 |
10/19/2037 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
09/30/2021 |
59572063255 |
Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack |
08/18/2021 |
92.58 |
3950.06 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2015 |
1875.00 |
None |
This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
09/30/2021 |
59572063106 |
Otezla, 30mg, Tablet, 60 pack |
08/18/2021 |
92.58 |
3950.06 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2014 |
1875.00 |
None |
This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
55513036955 |
Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack |
01/22/2021 |
265.79 |
3857.48 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2020 |
3591.69 |
None |
This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
09/30/2021 |
55513036955 |
Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack |
08/18/2021 |
92.58 |
3950.06 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2020 |
3591.69 |
None |
This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
59572063255 |
Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pk |
01/22/2021 |
265.79 |
3857.48 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2015 |
1875.00 |
None |
This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
55513013760 |
Otezla, 30mg, Tablet, 60 pack |
01/22/2021 |
265.79 |
3857.48 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2020 |
3591.69 |
None |
This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
09/30/2021 |
55513013760 |
Otezla, 30mg, Tablet, 60 pack |
08/18/2021 |
92.58 |
3950.06 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2020 |
3591.69 |
None |
This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000069 |
Amgen |
03/31/2021 |
59572063106 |
Otezla, 30mg, Tablet, 60 pk |
01/22/2021 |
265.79 |
3857.48 |
05/29/2034 |
Single Source Drug |
None |
1 |
Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines.
Our approach to pricing across the globe is underpinned by two simple core principles:
I. Pricing our products according to the value they deliver
II. Employs flexible pricing approaches to ensure patient access |
None |
None |
1 |
11/21/2019 |
Celgene |
13400000000 |
None |
None |
3398.00 |
3283.09 |
2014 |
1875.00 |
None |
This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896066930 |
Emverm Oral Tablet Chewable 100 MG, Package size of 1 |
02/15/2021 |
46.07 |
511.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
405.53 |
369.00 |
2017 |
369.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069701 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 100 |
02/15/2021 |
96.80 |
583.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
381.56 |
381.56 |
2013 |
278.45 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069713 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 60 |
02/15/2021 |
58.08 |
349.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
228.94 |
228.94 |
2013 |
167.07 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069801 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 100 |
02/15/2021 |
134.23 |
808.75 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
529.13 |
529.13 |
2013 |
386.15 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069813 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 60 |
02/15/2021 |
80.54 |
485.26 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
317.48 |
317.48 |
2013 |
231.69 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069901 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 100 |
02/15/2021 |
171.68 |
1034.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
676.74 |
676.74 |
2013 |
493.86 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069913 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 60 |
02/15/2021 |
103.01 |
620.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
406.05 |
406.05 |
2013 |
296.32 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896070001 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 100 |
02/15/2021 |
247.10 |
1488.82 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
974.06 |
974.06 |
2013 |
710.84 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896070013 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 60 |
02/15/2021 |
148.26 |
893.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
584.44 |
584.44 |
2013 |
426.50 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896070101 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 100 |
02/15/2021 |
322.53 |
1943.28 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
1271.39 |
1271.39 |
2013 |
927.82 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896070113 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 60 |
02/15/2021 |
193.52 |
1165.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
762.84 |
762.84 |
2013 |
556.69 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069501 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 100 |
02/15/2021 |
50.41 |
303.72 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
198.71 |
198.71 |
2013 |
145.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069513 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 60 |
02/15/2021 |
30.24 |
182.22 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
119.22 |
119.22 |
2013 |
87.01 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069601 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 100 |
02/15/2021 |
73.60 |
443.44 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
290.12 |
290.12 |
2013 |
211.72 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896069613 |
oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 60 |
02/15/2021 |
44.16 |
266.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
174.07 |
174.07 |
2013 |
127.03 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896066101 |
Rytary Oral Capsule Extended Release 23.75-95 MG, Package size of 100 |
02/15/2021 |
15.07 |
350.05 |
12/26/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
291.68 |
258.41 |
2015 |
230.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896066201 |
Rytary Oral Capsule Extended Release 36.25-145 MG, Package size of 100 |
02/15/2021 |
15.07 |
350.05 |
12/26/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
291.68 |
258.41 |
2015 |
230.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896066301 |
Rytary Oral Capsule Extended Release 48.75-195 MG, Package size of 100 |
02/15/2021 |
15.07 |
350.05 |
12/26/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
291.68 |
258.41 |
2015 |
230.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
64896066401 |
Rytary Oral Capsule Extended Release 61.25-245 MG, Package size of 100 |
02/15/2021 |
18.94 |
439.86 |
12/26/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/07/2018 |
IMPAX |
None |
1 |
This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company. |
366.51 |
324.69 |
2015 |
289.00 |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080501 |
Unithroid Oral Tablet 100 MCG, Package size of 100 |
02/15/2021 |
30.42 |
337.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080601 |
Unithroid Oral Tablet 112 MCG, Package size of 100 |
02/15/2021 |
30.48 |
338.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080701 |
Unithroid Oral Tablet 125 MCG, Package size of 100 |
02/15/2021 |
30.53 |
338.96 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080801 |
Unithroid Oral Tablet 137 MCG, Package size of 100 |
02/15/2021 |
30.57 |
339.32 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080901 |
Unithroid Oral Tablet 150 MCG, Package size of 100 |
02/15/2021 |
30.59 |
339.59 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846081001 |
Unithroid Oral Tablet 175 MCG, Package size of 100 |
02/15/2021 |
30.64 |
340.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846081101 |
Unithroid Oral Tablet 200 MCG, Package size of 100 |
02/15/2021 |
30.67 |
340.42 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080101 |
Unithroid Oral Tablet 25 MCG, Package size of 100 |
02/15/2021 |
30.25 |
335.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846081201 |
Unithroid Oral Tablet 300 MCG, Package size of 100 |
02/15/2021 |
30.70 |
340.76 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080201 |
Unithroid Oral Tablet 50 MCG, Package size of 100 |
02/15/2021 |
30.27 |
336.03 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080301 |
Unithroid Oral Tablet 75 MCG, Package size of 100 |
02/15/2021 |
30.30 |
336.41 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000122 |
Amneal Pharmaceuticals |
03/31/2021 |
60846080401 |
Unithroid Oral Tablet 88 MCG, Package size of 100 |
02/15/2021 |
30.37 |
337.15 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559067030 |
Arimidex (anastrozole) Tablets 1.0mg-30 |
03/05/2021 |
134.78 |
1632.37 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559052201 |
Inderal LA (propranolol hydrochloride) Long-Acting Cap 120mg-100 |
03/05/2021 |
670.45 |
8119.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559052301 |
Inderal LA (propranolol hydrochloride) Long-Acting Cap 160mg-100 |
03/05/2021 |
699.89 |
8476.47 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559052101 |
Inderal LA (propranolol hydrochloride) Long-Acting Capsules 80mg-100 |
03/05/2021 |
608.80 |
7373.21 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559052001 |
Inderal LA (propranolol Hydrocholoride) Long-Acting Capsules 60mg-100 |
03/05/2021 |
521.22 |
6312.57 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559060130 |
Inderal XL (propranolol hydrochloride) Extended Release Capsule 120mg-30 |
03/05/2021 |
180.34 |
2184.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559060030 |
Inderal XL (propranolol hydrochloride) Extended Release Capsule 80mg-30 |
03/05/2021 |
180.34 |
2184.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559059130 |
Innopran XL (propranolol hydrochloride) Extended Release Capsules 120mg-30 |
03/05/2021 |
180.34 |
2184.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000176 |
ANIP |
03/31/2021 |
62559059030 |
Innopran XL (propranolol hydrochloride) Extended Release Capsules 80mg-30 |
03/05/2021 |
180.34 |
2184.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505437703 |
PAXIL CR FCT 12.5MG 30BTL USA |
10/19/2021 |
21.55 |
239.42 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505437803 |
PAXIL CR FCT 25MG 30BTL USA |
10/19/2021 |
22.48 |
249.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505437903 |
PAXIL CR FCT 37.5MG 30BTL USA |
10/19/2021 |
23.16 |
257.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505451703 |
PAXIL FCT 10MG 30BTL USA |
10/19/2021 |
20.92 |
232.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505451803 |
PAXIL FCT 20MG 30BTL USA |
10/19/2021 |
21.83 |
242.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505451903 |
PAXIL FCT 30MG 30BTL USA |
10/19/2021 |
22.49 |
249.87 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505452003 |
PAXIL FCT 40MG 30BTL USA |
10/19/2021 |
23.76 |
263.95 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
12/31/2021 |
60505040205 |
PAXIL O/SUSP 10MG/5ML 250ML BTL USA1 |
10/19/2021 |
36.32 |
403.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000271 |
Apotex Corp |
06/30/2021 |
60505003307 |
PENTOXIFYLLINE XR Film Coated Table (FCT) 400MG 500 BTL |
04/20/2021 |
71.82 |
205.20 |
None |
Non-innovator Multiple Source Drug |
38316 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000132 |
Arbor Pharmaceuticals, LLC |
03/31/2021 |
24338001018 |
Bidil 20mg/37.5mg Tablet 180 Count Bottle |
01/01/2021 |
20.10 |
690.06 |
None |
Innovator Multiple Source Drug |
51766 |
None |
PBM Rebates; Increased Costs; Government Program Fees; Previous Price Increases |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
We are submitting under protest as we do not believe that we are required to report. There was no effective price in 2019 as the price on 1/1/2019 was the only price available. |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2021 |
13913001201 |
Cambia (diclofenac potassium) 50MG Oral 1 Packet |
01/03/2021 |
8.23 |
91.34 |
06/16/2026 |
Single Source Drug |
None |
1 |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see cost increase factors statement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years.
Comment on data element #8: While this is an active NDC in the compendia, we did not have any sales of the single unit NDC. We attempted to put 0 in this field but the validation failed so based on guidance from CA we are indicating non-public in data element #9. There were no US Sales of this NDC in 2020. |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2021 |
13913001203 |
Cambia (diclofenac potassium) 50MG Oral 9 Packets |
01/03/2021 |
74.05 |
822.03 |
06/16/2026 |
Single Source Drug |
87045 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see cost increase factors statement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000075 |
Assertio Therapeutics, Inc. |
03/31/2021 |
13913000812 |
Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle |
01/03/2021 |
155.48 |
1726.03 |
02/24/2029 |
Single Source Drug |
19458 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see cost increase factors statement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years |
| Rx0000048 |
Astellas Pharma US, Inc. |
03/31/2021 |
00469260130 |
Myrbetriq® 25mg 30 Tablet |
01/05/2021 |
12.15 |
417.19 |
03/28/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. |
| Rx0000048 |
Astellas Pharma US, Inc. |
03/31/2021 |
00469260190 |
Myrbetriq® 25mg 90 Tablet |
01/05/2021 |
36.45 |
1251.57 |
03/28/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. |
| Rx0000048 |
Astellas Pharma US, Inc. |
03/31/2021 |
00469260230 |
Myrbetriq® 50mg 30 Tablet |
01/05/2021 |
12.15 |
417.19 |
03/28/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. |
| Rx0000048 |
Astellas Pharma US, Inc. |
03/31/2021 |
00469260290 |
Myrbetriq® 50mg 90 Tablet |
01/05/2021 |
36.45 |
1251.57 |
03/28/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. |
| Rx0000058 |
Avanir Pharmaceuiticals |
03/31/2021 |
64597030160 |
Nuedexta Oral Capsule 20-10 mg 60 pack |
01/01/2021 |
84.60 |
1335.00 |
08/13/2026 |
Single Source Drug |
None |
1 |
Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors. As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability. Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The reason for the blank acquisition-related fields is that Neudexta was not acquired. |
| Rx0000277 |
Avion Pharmaceuticals, LLC |
03/31/2021 |
75854060228 |
BALCOLTRA Oral Tablet 0.1-20 MG-MCG |
01/31/2021 |
18.57 |
224.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years. |
| Rx0000277 |
Avion Pharmaceuticals, LLC |
03/31/2021 |
75854060203 |
BALCOLTRA Oral Tablet 0.1-20 MG-MCG (21) |
01/31/2021 |
55.73 |
674.92 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035310 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL |
01/01/2021 |
23.91 |
502.17 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035305 |
ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL |
01/01/2021 |
11.95 |
251.09 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208062901 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 10mL |
01/01/2021 |
22.01 |
462.10 |
01/13/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208062902 |
BEPREVE™ Ophthalmic Solution USP, 1.5%, 5mL |
01/01/2021 |
11.51 |
241.61 |
01/13/2025 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208044605 |
BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL |
01/01/2021 |
10.77 |
190.29 |
01/09/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208000401 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 2.5mL |
01/01/2021 |
10.96 |
193.73 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208000403 |
ISTALOL™ Ophthalmic Solution USP, 0.5%, 5mL |
01/01/2021 |
21.93 |
387.43 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208080060 |
LACRISERT® (hydroxypropyl cellulose ophthalmic insert), 5mg, 60 Sterile Ophthalmic Inserts |
01/01/2021 |
31.89 |
563.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050307 |
LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g |
01/01/2021 |
12.13 |
214.30 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208044335 |
LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g |
01/01/2021 |
17.07 |
301.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029910 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL |
01/01/2021 |
30.24 |
534.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029915 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL |
01/01/2021 |
44.95 |
794.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208029905 |
LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL |
01/01/2021 |
15.12 |
267.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208060203 |
PROLENSA™ (bromfenac ophthalmic solution) 0.07% 3mL |
01/01/2021 |
16.96 |
299.63 |
11/11/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081205 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.25%, 5mL |
01/01/2021 |
11.07 |
195.55 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081310 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 10mL |
01/01/2021 |
15.35 |
271.14 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081305 |
TIMOPTIC® (Timolol Maleate Ophthalmic Solution) 0.50%, 5mL |
01/01/2021 |
11.98 |
211.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081425 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.25%, 5mL |
01/01/2021 |
12.95 |
228.79 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208081605 |
TIMOPTIC-XE® (Timolol Maleate Ophthalmic Gel Forming Solution) 0.50%, 5mL |
01/01/2021 |
14.19 |
250.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050402 |
VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL |
01/01/2021 |
12.13 |
214.38 |
10/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208050405 |
VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, 5mL |
01/01/2021 |
24.27 |
428.77 |
10/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208053535 |
ZIRGAN™ (Ganciclovir Ophthalmic Gel 0.15%), 5mL |
01/01/2021 |
22.34 |
394.68 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035810 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL |
01/01/2021 |
31.47 |
555.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000096 |
Bausch + Lomb, Inc. |
03/31/2021 |
24208035805 |
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL |
01/01/2021 |
15.74 |
277.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581030 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct |
01/01/2021 |
117.61 |
1606.27 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581130 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct |
01/01/2021 |
155.03 |
2117.46 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187581230 |
APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct |
01/01/2021 |
352.80 |
4818.71 |
06/27/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006410 |
ATIVAN® Tablets 1mg 1,000s |
01/01/2021 |
2756.36 |
37647.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006301 |
ATIVAN® Tablets .5mg 100s |
01/01/2021 |
210.68 |
2877.54 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006401 |
ATIVAN® Tablets 1mg 100s |
01/01/2021 |
281.44 |
3843.97 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187006501 |
ATIVAN® Tablets 2mg 100s |
01/01/2021 |
448.52 |
6126.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
25010030515 |
DEMSER® (metyrosine), 250mg Capsules, 100ct |
01/01/2021 |
2210.87 |
39058.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187410010 |
LIBRAX Oral Capsule 5-2.5 MG (Chlordiazepoxide Hydrochloride and Clidinium Bromide), 100ct |
01/01/2021 |
362.02 |
4944.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301220 |
MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle |
01/01/2021 |
78.88 |
1393.51 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301030 |
MESTINON 60mg TABLETS 100s (pyridostigmine bromide) |
01/01/2021 |
97.11 |
1715.62 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187301330 |
MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT |
01/01/2021 |
55.26 |
976.21 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
66490069110 |
MYSOLINE 250 mg TABLETS, 100s (primidone) |
01/01/2021 |
403.73 |
5514.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
66490069010 |
MYSOLINE 50 mg TABLETS, 100s (primidone) |
01/01/2021 |
117.32 |
1602.38 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187305050 |
ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump |
01/01/2021 |
35.56 |
628.27 |
08/05/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187442010 |
PEPCID® (Famotidine) Tablets, 20mg, 100 |
01/01/2021 |
89.73 |
1225.53 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187442030 |
PEPCID® (Famotidine) Tablets, 20mg, 30 |
01/01/2021 |
26.92 |
367.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187444010 |
PEPCID® (Famotidine) Tablets, 40mg, 100 |
01/01/2021 |
173.43 |
2368.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187444030 |
PEPCID® (Famotidine) Tablets, 40mg, 30 |
01/01/2021 |
52.02 |
710.58 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187149825 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct |
01/01/2021 |
26.60 |
469.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187149605 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL, 60ct |
01/01/2021 |
30.33 |
535.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073030 |
WELLBUTRIN® XL 150mg Tablets, 30ct |
01/01/2021 |
116.11 |
1585.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073090 |
WELLBUTRIN® XL 150mg Tablets, 90ct |
01/01/2021 |
348.36 |
4757.94 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187073130 |
WELLBUTRIN® XL 300mg Tablets, 30ct |
01/01/2021 |
153.27 |
2093.43 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000097 |
Bausch Health US, LLC |
03/31/2021 |
00187045302 |
ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct |
01/01/2021 |
274.38 |
4847.28 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002260 |
Belbuca 150 mcg, film, 60ct box |
01/01/2021 |
17.44 |
366.26 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002360 |
Belbuca 300 mcg, film, 60ct box |
01/01/2021 |
27.39 |
575.22 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
437.53 |
401.40 |
2015 |
401.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002460 |
Belbuca 450 mcg, film, 60ct box |
01/01/2021 |
37.22 |
781.58 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
594.49 |
545.40 |
2015 |
545.40 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002560 |
Belbuca 600 mcg, film, 60ct box |
01/01/2021 |
39.71 |
834.00 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
634.38 |
582.00 |
2015 |
582.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002160 |
Belbuca 75 mcg, film, 60ct box |
01/01/2021 |
17.44 |
366.26 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
278.60 |
255.60 |
2015 |
255.60 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002660 |
Belbuca 750 mcg, film, 60ct box |
01/01/2021 |
41.76 |
877.00 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
667.08 |
612.00 |
2015 |
612.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385002760 |
Belbuca 900 mcg, film, 60ct box |
01/01/2021 |
42.99 |
902.79 |
12/21/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2017 |
Endo Pharmaceuticals |
7536000 |
None |
Acquisition price reflects cumulative price for NDCs: 59384002160, 59384002260, 59384002360, 59384002460, 59384002560, 59384002660, and 59384002760. |
686.70 |
630.00 |
2015 |
630.00 |
None |
None |
| Rx0000233 |
BioDelivery Sciences International, Inc. |
03/31/2021 |
59385004130 |
Symproic .2mg mg tablet, 30 ct bottle |
01/01/2021 |
18.86 |
395.97 |
11/11/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/04/2019 |
Shionogi Inc. |
30000000 |
None |
None |
313.95 |
313.95 |
2017 |
313.95 |
None |
None |
| Rx0000099 |
Biogen |
03/31/2021 |
64406000801 |
TYSABRI (natalizumab) Injection 300 mg/15 mL (20 mg/mL) solution in a single-dose vial |
01/01/2021 |
372.31 |
7463.99 |
03/05/2027 |
Single Source Drug |
None |
1 |
Multiple factors are considered when determining price increases, including the continued level of R&D investment in the product, as well as the product?s value to patients, present and future benefits to society, and fulfilling Biogen?s commitment to innovation, affordability and sustainability. |
None |
This increase was not necessitated by a change or improvement in the product. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Tysabri was not acquired by Biogen from another company in the last 5 years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597000201 |
APTIVUS 100MG/ML SOLUTION 95 |
01/01/2021 |
23.64 |
614.73 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=471 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597000302 |
APTIVUS 250MG CAPSULE 120 |
01/01/2021 |
70.93 |
1844.29 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=472 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597008717 |
ATROVENT HFA 17mcg Canister 12.9 |
01/01/2021 |
16.46 |
427.85 |
01/17/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=482 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003134 |
CATAPRES TTS-1 0.1mg PATCH 4 |
01/01/2021 |
11.16 |
290.24 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=476 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003234 |
CATAPRES TTS-2 0.2mg PATCH 4 |
01/01/2021 |
18.80 |
488.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=477 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003334 |
CATAPRES TTS-3 0.3mg PATCH 4 |
01/01/2021 |
26.07 |
677.93 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=478 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597002402 |
COMBIVENT RESPIMAT 20-100mcg Cartridge 4 |
01/01/2021 |
17.06 |
443.51 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=473 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014130 |
GILOTRIF 20MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=495 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597013730 |
GILOTRIF 30MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=490 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597013830 |
GILOTRIF 40MG TABLET 30 |
01/01/2021 |
570.70 |
10082.42 |
07/05/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=491 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015230 |
JARDIANCE 10MG TABLET 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=504 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015237 |
JARDIANCE 10MG TABLET 3x10 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=505 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015290 |
JARDIANCE 10MG TABLET 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=506 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015330 |
JARDIANCE 25MG TABLET 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=507 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015337 |
JARDIANCE 25MG TABLET 3x10 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=508 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015390 |
JARDIANCE 25MG TABLET 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=509 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014818 |
JENTADUETO 2.5MG-1000MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=502 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014860 |
JENTADUETO 2.5MG-1000MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=503 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014618 |
JENTADUETO 2.5MG-500MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=498 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014660 |
JENTADUETO 2.5MG-500MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=499 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014718 |
JENTADUETO 2.5MG-850MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=500 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014760 |
JENTADUETO 2.5MG-850MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
06/04/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=501 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027094 |
JENTADUETO XR 2.5MG-1000MG Tablet 180 |
01/01/2021 |
69.35 |
1456.37 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=523 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027073 |
JENTADUETO XR 2.5MG-1000MG Tablet 60 |
01/01/2021 |
23.12 |
485.46 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=522 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027533 |
JENTADUETO XR 5MG-1000MG Tablet 30 |
01/01/2021 |
23.12 |
485.46 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=524 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597027581 |
JENTADUETO XR 5MG-1000MG Tablet 90 |
01/01/2021 |
69.35 |
1456.37 |
03/06/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=525 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010930 |
MIRAPEX ER 0.375MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=486 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028530 |
MIRAPEX ER 0.75MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=528 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011330 |
MIRAPEX ER 1.5MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=487 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028630 |
MIRAPEX ER 2.25MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=529 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011530 |
MIRAPEX ER 3.0MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=488 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028730 |
MIRAPEX ER 3.75MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=530 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597011630 |
MIRAPEX ER 4.5MG TABLET 30 |
01/01/2021 |
25.35 |
659.08 |
09/08/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=489 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597003001 |
MOBIC 15MG TABLET 100 |
01/01/2021 |
54.71 |
1422.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=475 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597002901 |
MOBIC 7.5MG TABLET 100 |
01/01/2021 |
35.78 |
930.31 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=474 |
For Column F there are no unexpired patents for this product per the Orange Book. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014360 |
OFEV 100MG CAPSULE 60 |
01/01/2021 |
629.07 |
11113.60 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=496 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014560 |
OFEV 150MG CAPSULE 60 |
01/01/2021 |
629.07 |
11113.60 |
06/07/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=497 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010854 |
PRADAXA 110MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=484 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010860 |
PRADAXA 110MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=485 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597036082 |
PRADAXA 150MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=540 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597036055 |
PRADAXA 150MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=539 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597035556 |
PRADAXA 75MG CAPSULE 10x6 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=538 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597035509 |
PRADAXA 75MG CAPSULE 60 |
01/01/2021 |
18.34 |
476.92 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=537 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597019705 |
PRAXBIND 2.5g/50mL Vials 2 |
01/01/2021 |
272.46 |
4279.26 |
07/20/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=521 |
For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007541 |
SPIRIVA HANDIHALER 18mcg Blister Card 30 |
01/01/2021 |
22.76 |
478.00 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=479 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007575 |
SPIRIVA HANDIHALER 18mcg Blister Card 5 |
01/01/2021 |
4.51 |
94.67 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=481 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597007547 |
SPIRIVA HANDIHALER 18mcg Blister Card 90 |
01/01/2021 |
68.29 |
1434.01 |
04/19/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=480 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016061 |
SPIRIVA RESPIMAT 1.25mcg Cartridge 4 |
01/01/2021 |
22.76 |
478.00 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=513 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597010061 |
SPIRIVA RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
22.76 |
478.00 |
04/16/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=483 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015561 |
STIOLTO RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
16.86 |
438.38 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=510 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597019261 |
STRIVERDI RESPIMAT 2.5mcg Cartridge 4 |
01/01/2021 |
8.98 |
233.52 |
10/16/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=520 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016818 |
SYNJARDY 12.5-1000MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=514 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597016860 |
SYNJARDY 12.5-1000MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=515 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597018018 |
SYNJARDY 12.5-500MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=518 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597018060 |
SYNJARDY 12.5-500MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=519 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597017518 |
SYNJARDY 5-1000MG Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=516 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597017560 |
SYNJARDY 5-1000MG Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=517 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015918 |
SYNJARDY 5-500MG TABLET 180 |
01/01/2021 |
78.36 |
1645.61 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=511 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597015960 |
SYNJARDY 5-500MG TABLET 60 |
01/01/2021 |
26.12 |
548.54 |
04/03/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=512 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028073 |
SYNJARDY XR 10mg-1000mg Tablet 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=526 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597028090 |
SYNJARDY XR 10mg-1000mg Tablet 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=527 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597030093 |
SYNJARDY XR 12.5mg-1000mg Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=536 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597030045 |
SYNJARDY XR 12.5mg-1000mg Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=535 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029588 |
SYNJARDY XR 25mg-1000mg Tablet 30 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=534 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029578 |
SYNJARDY XR 25mg-1000mg Tablet 90 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=533 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029059 |
SYNJARDY XR 5mg-1000mg Tablet 180 |
01/01/2021 |
78.36 |
1645.61 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=531 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597029074 |
SYNJARDY XR 5mg-1000mg Tablet 60 |
01/01/2021 |
26.12 |
548.54 |
06/11/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=532 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014061 |
TRADJENTA 5MG TABLET 100 |
01/01/2021 |
77.06 |
1618.19 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=493 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014030 |
TRADJENTA 5MG TABLET 30 |
01/01/2021 |
23.12 |
485.46 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=492 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000038 |
Boehringer Ingelheim |
03/31/2021 |
00597014090 |
TRADJENTA 5MG TABLET 90 |
01/01/2021 |
69.35 |
1456.37 |
03/05/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=494 |
For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years. |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089321 |
ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
28.25 |
499.07 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089331 |
ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets |
01/01/2021 |
47.09 |
831.85 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089470 |
ELIQUIS 5 MG Tablet Bottle of 74 Tablets |
01/01/2021 |
34.84 |
615.53 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003376474 |
ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs) |
01/01/2021 |
34.84 |
615.53 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089421 |
ELIQUIS 5 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
28.25 |
499.07 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003089431 |
ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100 |
01/01/2021 |
47.09 |
831.85 |
02/24/2031 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218851 |
ORENCIA 125 MG/ML Solution, 1ML Single Dose Prefilled Auto-injector, Package of 4 Auto-Injectors |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218811 |
ORENCIA 125 MG/ML Solution, 1ml Single Dose Prefilled Syringe , Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003218713 |
ORENCIA 250 MG Solution Vial W/ Syringe, Package contains 1 Vial |
01/01/2021 |
52.90 |
1228.47 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003281411 |
ORENCIA 50 MG/0.4ML Solution, 0.4ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003281811 |
ORENCIA 87.5 MG/0.7ML Solution, 0.7ML Single Dose Prefilled Syringe, Package of 4 Syringes |
01/01/2021 |
208.87 |
4850.49 |
02/18/2028 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085222 |
SPRYCEL 100 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085722 |
SPRYCEL 140 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052711 |
SPRYCEL 20 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
362.23 |
8411.82 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052811 |
SPRYCEL 50 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
724.46 |
16823.60 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003052411 |
SPRYCEL 70 MG Tablet, Bottle of 60 Tablets |
01/01/2021 |
724.46 |
16823.60 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000078 |
Bristol Myers Squibb |
03/31/2021 |
00003085522 |
SPRYCEL 80 MG Tablet, Bottle of 30 Tablets |
01/01/2021 |
652.86 |
15160.86 |
09/28/2026 |
Single Source Drug |
None |
1 |
We consider multiple factors when setting a list price for a medicine, including:
? The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs.
? Market and business considerations, including:
o Ongoing research-investment costs; BMS invests more than 35% of its annual revenues in R&D, among the highest of any large company in any industry in the world;
o Medical- and patient-service costs; this includes funding growing patient assistance programs;
o Inflationary and capital-investment costs associated with manufacturing, storage and supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was developed by BMS |
| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020202 |
CetacaineAnesthetic Liquid 14g |
01/01/2021 |
24.05 |
105.30 |
None |
Non-innovator Multiple Source Drug |
8690 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020204 |
CetacaineAnesthetic Liquid 30g |
01/01/2021 |
27.20 |
165.10 |
None |
Non-innovator Multiple Source Drug |
17093 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000345 |
Cetylite Industries |
03/31/2021 |
10223020103 |
CetacaineAnesthetic Spray 20g |
01/01/2021 |
17.55 |
75.40 |
None |
Non-innovator Multiple Source Drug |
85156 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
10122051001 |
Curosurf® 1.5ml, 80 mg/ml poractant alfa |
02/06/2021 |
36.58 |
493.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
10122051003 |
Curosurf® 3.0ml, 80 mg/ml poractant alfa |
02/06/2021 |
72.14 |
973.88 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609000601 |
Ferriprox film-coated tablets 500mg 100ct |
01/04/2021 |
343.61 |
7215.73 |
06/28/2021 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609000705 |
Ferriprox film-coated tablets three-a-day 1000mg 50 ct |
01/04/2021 |
343.61 |
7215.73 |
06/28/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
03/31/2021 |
52609450207 |
Ferriprox Solution for oral use 100mg/ml 500ml bottle |
01/04/2021 |
343.61 |
7215.73 |
10/20/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2015 |
4533.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000358 |
Civica, Inc |
03/31/2021 |
72572025025 |
Heparin Sodium Injection Solution 1000 Unit/ML Vial Qty 25 |
02/01/2021 |
9.25 |
43.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/15/2019 |
Hikma |
0 |
1 |
Civica is selling under a non-exclusive license through a product supply agreement with the manufacturer (Hikma). There was no licensing fee, or acquisition price, only a fee per unit purchased from the manufacturer (Hikma). |
34.25 |
34.25 |
2011 |
65.50 |
None |
Civica does not own patent for this product. The information for the year_ introduced and WAC_ at_ introduction was sourced from Medi-Span for NDC 00641-0391-12 on April 28, 2021. |
| Rx0000358 |
Civica, Inc |
03/31/2021 |
72572025525 |
Heparin Sodium Injection Solution 5000 Unit/ML Vial Qty 25 |
02/01/2021 |
9.25 |
43.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/15/2019 |
Hikma |
0 |
1 |
Civica is selling under a non-exclusive license through a product supply agreement with the manufacturer (Hikma). There was no licensing fee, or acquisition price, only a fee per unit purchased from the manufacturer (Hikma). |
34.25 |
34.25 |
2011 |
65.50 |
None |
Civica does not own patent for this product. The information for the year_ introduced and WAC_ at_ introduction was sourced from Medi-Span for NDC 00641-0391-12 on April 28, 2021. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020191 |
Rubraca 200mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
3458 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=546, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=549 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020291 |
Rubraca 250mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
2822 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=547, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=550 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
06/30/2021 |
69660020391 |
Rubraca 300mg, 60 tabs/bottle |
04/01/2021 |
334.00 |
8685.00 |
08/17/2035 |
Single Source Drug |
15687 |
None |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
No change improvements |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=548, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=551 |
Product licensing was not acquired within the last 5 years. |
| Rx0000320 |
CMP Pharma |
12/31/2021 |
46287002004 |
CaroSpir spironolactone oral suspension 25mg/5ml 118ml |
10/01/2021 |
31.45 |
381.15 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2021 |
46287002001 |
CaroSpir spironolactone oral suspension 25mg/5ml 473ml |
10/01/2021 |
274.85 |
1527.85 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000604 |
Sodium Polystyrene Suspension 120ml enema kit |
03/08/2021 |
7.20 |
86.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000601 |
Sodium Polystyrene Suspension 473ml |
03/08/2021 |
12.00 |
144.60 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
03/31/2021 |
46287000660 |
Sodium Polystyrene Suspension 60ml unit dose X 10 |
03/08/2021 |
15.80 |
191.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011660 |
NUCYNTA ER, 100mg, tablet, 60 pack |
01/01/2021 |
82.71 |
918.17 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
835.46 |
760.20 |
2011 |
269.40 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510017460 |
NUCYNTA ER, 150mg, tablet, 60 pack |
01/01/2021 |
106.71 |
1184.60 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1077.89 |
980.79 |
2011 |
346.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510023260 |
NUCYNTA ER, 200mg, tablet, 60 pack |
01/01/2021 |
135.46 |
1503.78 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1368.32 |
1245.06 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510029160 |
NUCYNTA ER, 250mg, tablet, 60 pack |
01/01/2021 |
169.48 |
1881.39 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1711.91 |
1557.70 |
2011 |
441.60 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510005860 |
NUCYNTA ER, 50mg, tablet, 60 pack |
01/01/2021 |
44.72 |
496.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Nucynta ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta ER. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
451.74 |
411.05 |
2011 |
145.80 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510010010 |
NUCYNTA, 100mg, tablet, 100 pack |
01/01/2021 |
107.78 |
1196.49 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
1088.71 |
990.64 |
2009 |
265.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510005010 |
NUCYNTA, 50mg, tablet, 100 pack |
01/01/2021 |
69.21 |
768.34 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
699.13 |
636.15 |
2009 |
170.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510007510 |
NUCYNTA, 75mg, tablet, 100 pack |
01/01/2021 |
80.87 |
897.73 |
06/27/2025 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $330 Million since our inception. In addition, we continue to reinvest in Nucynta?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Nucynta. |
None |
None |
1 |
02/14/2020 |
Assertio Therapeutics, Inc. |
375000000 |
None |
None |
816.86 |
743.28 |
2009 |
199.00 |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011510 |
XTAMPZA ER, 13.5mg, capsule, 100 pack |
01/01/2021 |
71.37 |
792.29 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510012010 |
XTAMPZA ER, 18mg, capsule, 100 pack |
01/01/2021 |
90.51 |
1004.76 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510013010 |
XTAMPZA ER, 27mg, capsule, 100 pack |
01/01/2021 |
125.91 |
1397.71 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510014010 |
XTAMPZA ER, 36mg, capsule, 100 pack |
01/01/2021 |
154.97 |
1720.36 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2021 |
24510011010 |
XTAMPZA ER, 9mg, capsule, 100 pack |
01/01/2021 |
48.49 |
538.31 |
09/02/2036 |
Single Source Drug |
None |
1 |
While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $330 million since our inception. In addition, we continue to reinvest in Xtampza ER?s manufacturing infrastructure to maintain sufficient supply. These increases in costs and the ever-increasing demand for rebates to improve patient access, were all considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000154 |
Corcept Therapeutics Incorporated |
03/31/2021 |
76346007302 |
Korlym (mifepristone) 300mg Tablets 280-ct Bottles |
03/01/2021 |
7280.00 |
154000.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few ? or no ? good treatment options. In setting Korlym?s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000154 |
Corcept Therapeutics Incorporated |
03/31/2021 |
76346007301 |
Korlym (mifepristone) 300mg Tablets 28-ct Bottles |
03/01/2021 |
728.00 |
15400.00 |
08/22/2038 |
Single Source Drug |
None |
1 |
Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few ? or no ? good treatment options. In setting Korlym?s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000184 |
Cosette Pharmaceuticals, Inc. |
03/31/2021 |
00713016612 |
MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg, 12 Suppositories/Pack |
02/02/2021 |
168.36 |
1853.90 |
None |
Single Source Drug |
None |
1 |
Operating primarily as a manufacturer of generic and over-the-counter drug products, the Company has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, the Company carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, the Company is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio. |
None |
None |
1 |
06/28/2019 |
Horizon Therapeutics PLC |
None |
1 |
None |
70.23 |
39.96 |
1983 |
0.01 |
None |
WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W. |
| Rx0000062 |
Covis Pharma |
03/31/2021 |
70515061001 |
Prilosec (Omeprazole Magnesium) - 30 GRANULE 10mg - Delayed Release - in 1 CARTON |
01/04/2021 |
17.99 |
377.73 |
None |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
04/01/2017 |
AstraZeneca |
None |
1 |
None |
195.97 |
195.97 |
2003 |
195.07 |
None |
WAC at Intro to Market is unavailable so the earliest date in which WAC is known (i.e., 2015) has been entered. |
| Rx0000062 |
Covis Pharma |
03/31/2021 |
70515062501 |
Prilosec (Omeprazole Magnesium) - 30 GRANULE 2.5 mg- Delayed Release - in 1 CARTON |
01/04/2021 |
17.99 |
377.73 |
None |
Single Source Drug |
None |
1 |
Covis Pharma's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to a) the clinical and economic value of the medicine b) the therapeutic category, market dynamics, and competitor pricing; c) discounts provided to customers in the public and private sectors; and d) patient support provided by Covis Pharma to ensure patient access. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
04/01/2017 |
AstraZeneca |
None |
1 |
None |
195.97 |
195.97 |
2003 |
195.07 |
None |
WAC at Intro to Market is unavailable so the earliest date in which WAC is known (i.e., 2015) has been entered. |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220028708 |
Caldolor (ibuprofen) injection 800 mg/8ml for intravenous use; sold by the tray (25 vials/ tray) |
01/21/2021 |
26.02 |
459.80 |
09/14/2030 |
Single Source Drug |
1774383 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220028422 |
Caldolor prefilled IV bag (ibuprofen) 800mg/ 200ml is a nonsteroidal anti-inflammatory drug (NSAID) sold by the case of 20 premixed IV bags |
01/21/2021 |
116.58 |
416.58 |
09/30/2029 |
Single Source Drug |
2091074 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220071930 |
Lactulose 10 GM Packet for oral solution 30 EA UD |
01/21/2021 |
11.62 |
243.95 |
12/18/2031 |
Single Source Drug |
7678082 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220072930 |
Lactulose 20 GM Packet for oral solution 30 EA UD |
01/21/2021 |
12.03 |
252.79 |
12/18/2031 |
Single Source Drug |
7679507 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220031522 |
Telavancin HCl 750 MG Solution Reconstituted 1 EA UD sold in cases of 12 vials per case |
01/21/2021 |
19.64 |
510.80 |
01/01/2027 |
Single Source Drug |
14976477 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
06/30/2021 |
66220031522 |
Telavancin HCl 750 MG Solution Reconstituted 1 EA UD sold in cases of 12 vials per case |
06/10/2021 |
153.25 |
6282.84 |
01/01/2027 |
Single Source Drug |
34020 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2021 |
66220016010 |
Vaprisol (conivaptan hydrochloride) 20mg/ 100 ml for intravenous use: sold in multiples of 10 cartons/case |
01/21/2021 |
66.02 |
891.32 |
12/15/2019 |
Single Source Drug |
1745863 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
51267089099 |
Contrave Oral Tablet 120ct (naltrexone HCI/bupropion HCI) 8-90mg |
02/16/2021 |
25.61 |
303.60 |
07/20/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/26/2019 |
Nalpropion Pharmaceuticals LLC |
0 |
None |
The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies. |
277.99 |
277.99 |
2014 |
199.50 |
None |
The same private equity investor owned Currax Pharmaceuticals LLC and Nalpropion Pharmaceuticals LLC and merged the two companies. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Kit (sumatriptan succinate exhale powder) 11mg |
02/16/2021 |
69.60 |
940.00 |
10/20/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847010330 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 3mg |
02/16/2021 |
39.90 |
538.80 |
09/27/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847010630 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 6mg |
02/16/2021 |
39.90 |
538.80 |
09/27/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2021 |
42847085009 |
Treximet 9 tab/pk (sumatriptan/naproxen) 85 mg/500 mg |
02/16/2021 |
93.42 |
1261.53 |
04/02/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Pharmaceuticals |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
967.23 |
880.09 |
2015 |
625.00 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required y the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087122501 |
Cetrotide Subcutaneous Kit 0.25 MG Single |
01/15/2021 |
17.51 |
251.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087907001 |
Gonal-f Injection Solution Reconstituted 1050 UNIT Single |
01/15/2021 |
206.52 |
2960.18 |
08/23/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087903001 |
Gonal-f Injection Solution Reconstituted 450 UNIT Single |
01/15/2021 |
88.51 |
1268.65 |
08/23/2019 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087111501 |
Gonal-f RFF Rediject Subcutaneous Solution 300 UNIT/0.5ML Single |
01/15/2021 |
59.01 |
845.77 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087111601 |
Gonal-f RFF Rediject Subcutaneous Solution 450 UNT/0.75ML Single |
01/15/2021 |
88.51 |
1268.65 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087111701 |
Gonal-f RFF Rediject Subcutaneous Solution 900 UNIT/1.5ML Single |
01/15/2021 |
177.02 |
2537.30 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087900501 |
Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT (1) Single |
01/15/2021 |
14.75 |
211.44 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087900506 |
Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT (10), 10 Pack |
01/15/2021 |
147.52 |
2114.42 |
04/02/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400000 |
Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
4881.80 |
86244.30 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400004 |
Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
1952.72 |
34497.72 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400005 |
Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
2440.90 |
43122.15 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400006 |
Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
2929.08 |
51746.58 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400007 |
Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
3417.26 |
60371.01 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400008 |
Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
3905.44 |
68995.44 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087400009 |
Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG |
01/15/2021 |
4393.62 |
77619.87 |
10/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087115001 |
Ovidrel Subcutaneous Injectable 250 MCG/0.5ML Prefilled Syringe |
01/15/2021 |
13.31 |
190.80 |
03/16/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087332201 |
Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML (12 single use auto injector) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087332209 |
Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML (Single) |
01/15/2021 |
41.86 |
739.48 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087334401 |
Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML (12 single use auto injector) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087334409 |
Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML (Single) |
01/15/2021 |
41.86 |
739.48 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087018801 |
Rebif Rebidose Titration Pack Subcutaneous Solution Auto-injector 6X8.8 & 6X22 MCG (6 single use auto injector) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087002203 |
Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML (12 pre-filled syringes) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087002209 |
Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML (Single) |
01/15/2021 |
41.86 |
739.48 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087004403 |
Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML (12 pre-filled syringes) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087004409 |
Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML (Single) |
01/15/2021 |
41.86 |
739.48 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087882201 |
Rebif Titration Pack Subcutaneous Solution Prefilled Syringe 6X8.8 & 6X22 MCG (6 pre-filled syringes) |
01/15/2021 |
502.29 |
8873.74 |
02/08/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087100502 |
Saizen Injection Solution Reconstituted 5 MG, Single |
01/15/2021 |
39.50 |
697.60 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087108801 |
Saizen Injection Solution Reconstituted 8.8 MG, Single |
01/15/2021 |
63.19 |
1116.16 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087001601 |
Saizenprep Injection Solution Reconstituted 8.8 MG, Single |
01/15/2021 |
63.19 |
1116.16 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087000407 |
Serostim Subcutaneous Solution Reconstituted 4 MG, 7 pack |
01/15/2021 |
161.88 |
2857.12 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087000507 |
Serostim Subcutaneous Solution Reconstituted 5 MG, 7 pack |
01/15/2021 |
202.35 |
3571.40 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000079 |
EMD Serono, Inc. |
03/31/2021 |
44087000607 |
Serostim Subcutaneous Solution Reconstituted 6 MG, 7 pack |
01/15/2021 |
242.82 |
4285.68 |
04/27/2016 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2021 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
04/01/2021 |
65.54 |
1416.83 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 7/15/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244001002 |
Edex, Alprostadil For Inj Kit 10 MCG, 2 |
01/01/2021 |
8.10 |
143.17 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244001006 |
Edex, Alprostadil For Inj Kit 10 MCG, 6 |
01/01/2021 |
24.32 |
429.57 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244002002 |
Edex, Alprostadil For Inj Kit 20 MCG, 2 |
01/01/2021 |
10.47 |
184.96 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244002006 |
Edex, Alprostadil For Inj Kit 20 MCG, 6 |
01/01/2021 |
31.41 |
554.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244004002 |
Edex, Alprostadil For Inj Kit 40 MCG, 2 |
01/01/2021 |
14.30 |
252.58 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244004006 |
Edex, Alprostadil For Inj Kit 40 MCG, 6 |
01/01/2021 |
42.89 |
757.69 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481002509 |
FROVA, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 |
01/01/2021 |
87.08 |
966.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481068706 |
LIDODERM, Lidocaine Patch 5%, 30 |
01/01/2021 |
59.31 |
658.39 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481062970 |
PERCOCET, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 |
01/01/2021 |
254.82 |
2828.74 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481062770 |
PERCOCET, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 |
01/01/2021 |
128.88 |
1430.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481062370 |
PERCOCET, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 |
01/01/2021 |
180.38 |
2002.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481062385 |
PERCOCET, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 |
01/01/2021 |
879.21 |
9760.13 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
63481062870 |
PERCOCET, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 |
01/01/2021 |
194.88 |
2163.33 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2021 |
67979000201 |
Supprelin LA, 50 mg implant, ea |
04/01/2021 |
2011.79 |
43068.82 |
06/16/2026 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 7/15/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244010010 |
THEO-24, Theophylline Cap ER 24HR 100 MG, 100 |
01/01/2021 |
23.89 |
265.23 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244020010 |
THEO-24, Theophylline Cap ER 24HR 200 MG, 100 |
01/01/2021 |
35.51 |
394.19 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244030010 |
THEO-24, Theophylline Cap ER 24HR 300 MG, 100 |
01/01/2021 |
43.64 |
484.49 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
03/31/2021 |
52244040010 |
THEO-24, Theophylline Cap ER 24HR 400 MG, 100 |
01/01/2021 |
61.41 |
681.74 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the ?Patent Expiration Date? field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2021 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
04/01/2021 |
324.13 |
7007.25 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/15/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000091 |
Endo Pharmaceuticals Inc. |
06/30/2021 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
04/01/2021 |
196.46 |
5233.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration?s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For ?Year Introduced?, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
| Rx0000094 |
Epic Pharma |
09/30/2021 |
42806008101 |
Benzphetamine Hydrochloride 50mg Oral 100 tablet |
07/01/2021 |
740.00 |
950.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Epic Pharma developed the product |
| Rx0000094 |
Epic Pharma |
09/30/2021 |
42806008130 |
Benzphetamine Hydrochloride 50mg Oral 30 tablet |
07/01/2021 |
315.00 |
390.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Epic Pharma developed the product |
| Rx0000094 |
Epic Pharma |
09/30/2021 |
42806026301 |
Isradipine 2.5mg Oral 100 capsule |
07/07/2021 |
406.37 |
976.37 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Epic Pharma developed the product |
| Rx0000094 |
Epic Pharma |
09/30/2021 |
42806026401 |
Isradipine 5mg Oral 100 capsule |
07/07/2021 |
147.53 |
987.53 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Epic Pharma developed the product |
| Rx0000104 |
EUSA Pharma (US) LLC |
12/31/2021 |
73090042101 |
SYLVANT 1 Vial of 400mg, intravenous powder for solution |
10/01/2021 |
143.99 |
4943.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
3640.96 |
3534.92 |
2014 |
3332.00 |
None |
None |
| Rx0000104 |
EUSA Pharma (US) LLC |
12/31/2021 |
73090042001 |
SYLVANT 1 Vial of100mg, intravenous powder for solution |
10/01/2021 |
36.00 |
1235.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
910.24 |
883.73 |
2014 |
833.00 |
None |
None |
| Rx0000104 |
EUSA Pharma (US) LLC |
06/30/2021 |
73090042001 |
SYLVANT, 100mg, intravenous POW for solution |
05/01/2021 |
26.63 |
1199.89 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
910.24 |
None |
2014 |
833.00 |
None |
EUSA Pharma transitioned SYLVANT's NDC from 57894-0420-01 to 73090-0420-01 and from 57894-0421-01 to 73090-0421-01 respectively. |
| Rx0000104 |
EUSA Pharma (US) LLC |
06/30/2021 |
73090042101 |
SYLVANT, 400mg, intravenous POW for solution |
05/01/2021 |
106.53 |
4799.56 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/22/2018 |
Janssen Biotech |
115000000 |
None |
Acquisition price is for both NDCs |
3640.96 |
None |
2014 |
3332.00 |
None |
EUSA Pharma transitioned SYLVANT's NDC from 57894-0420-01 to 73090-0420-01 and from 57894-0421-01 to 73090-0421-01 respectively. |
| Rx0000010 |
Exelixis, Inc. |
03/31/2021 |
42388002426 |
CABOMETYX 20MG 30 TAB BTL EACH |
01/01/2021 |
1511.36 |
21662.80 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis’ Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis’ revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery and Development Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. As part of these efforts, Exelixis has advanced three candidates to Phase 1 clinical trials, and anticipates filing INDs for up to two additional candidates in 2021. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to CABOMETYX’s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib’s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer, including a recent approval for the treatment of 1st line kidney cancer in combination with nivolumab, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX® when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/13/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2021 |
42388002526 |
CABOMETYX 40MG 30 TAB BTL EACH |
01/01/2021 |
1511.36 |
21662.80 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis’ Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis’ revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery and Development Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. As part of these efforts, Exelixis has advanced three candidates to Phase 1 clinical trials, and anticipates filing INDs for up to two additional candidates in 2021. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to CABOMETYX’s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib’s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer, including a recent approval for the treatment of 1st line kidney cancer in combination with nivolumab, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX® when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/13/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000010 |
Exelixis, Inc. |
03/31/2021 |
42388002326 |
CABOMETYX 60MG 30 TAB BTL EACH |
01/01/2021 |
1511.36 |
21662.80 |
07/09/2033 |
Single Source Drug |
None |
1 |
Exelixis’ Mission: Exelixis strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. That mission, however, entails tremendous risk of failure and research and development costs that total in the billions of dollars. At the present time, CABOMETYX® and COMETRIQ®, both derived from the same molecule, cabozantinib, are the only products that Exelixis sells and comprise the vast majority of Exelixis’ revenue. Exelixis is committed to spending the largest portion of this revenue on drug discovery research and clinical development, and to pricing CABOMETYX consistent with its value when compared to competitive products approved for similar conditions.
Drug Discovery and Development Factors: Having recently constructed new laboratory facilities, Exelixis re-launched its drug discovery activities in 2018 and is working to discover the next generation of cancer therapies. As part of these efforts, Exelixis has advanced three candidates to Phase 1 clinical trials, and anticipates filing INDs for up to two additional candidates in 2021. Exelixis considered the investments necessary to undertake and support these drug discovery and development efforts when it contemplated changes to CABOMETYX’s wholesale acquisition cost.
Cabozantinib Development Factors: Since the initial commercial launch of cabozantinib, Exelixis has received extensive additional data demonstrating that cabozantinib shows activity in an extremely broad and diverse collection of additional cancers. Alone and in combination with other therapies, it is currently being studied in over 100 clinical trials for over 20 different forms of cancer. Exelixis considered the cost of this clinical development program, and the need to expand it to reach cabozantinib’s full potential for treating the largest number of cancer patients, when it contemplated changes to the wholesale acquisition cost of CABOMETYX.
CABOMETYX Value Factors: CABOMETYX has been approved by the FDA to treat patients with liver and kidney cancer, including a recent approval for the treatment of 1st line kidney cancer in combination with nivolumab, and has shown impressive efficacy relative to its competitors in treating patients with these life-threatening diseases. It is the only drug of its kind to improve overall survival in a statistically significant manner in both kidney and liver cancer. When Exelixis contemplated a change to the wholesale acquisition cost for CABOMETYX, Exelixis considered the clinical value proposition of CABOMETYX relative to its competitor prescription drugs, as well as the competitive market generally and the existing price points of competitors.
CABOMETYX Cost Factors: At Exelixis, we are committed to ensuring that all patients in need can access our medicines. To secure that the supply of CABOMETYX for our customers, and ultimately, patients is safe and interrupted, Exelixis has expanded its supply chain network, establishing redundancies to prevent supply disruption. In addition, Exelixis has and continues to incur increasing costs in manufacturing due to volatility in the cost of raw materials and other inputs. When Exelixis contemplated changes to the wholesale acquisition cost of CABOMETYX, Exelixis considered these investments in expanding and improving our manufacturing capabilities and supply chain, as well as rising manufacturing costs. |
None |
It is Exelixis' stated mission to develop innovative, effective, tolerable and durable treatments for patients with cancer. To accomplish this, Exelixis has and continues to increase our investments in innovative research and development activities. In pre-clinical and clinical testing, cabozantinib has shown promising activity against many forms of cancer and Exelixis is therefore engaged in a very broad clinical development program aimed at improving cabozantinib by exploring the medicine's full therapeutic potential to help patients. To fund that program, and otherwise support our other research, development and business operations, it is necessary for Exelixis to increase the wholesale acquisition cost of CABOMETYX® when market conditions permit such an increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/13/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date |
| Rx0000205 |
Eyevance Pharmaceuticals LLC |
09/30/2021 |
71776010005 |
Flarex (fluorometholone acetate ophthalmic suspension 0.1%) 5mL Bottle Liquid |
08/03/2021 |
5.95 |
125.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/23/2018 |
Novartis AG |
None |
1 |
None |
70.01 |
66.05 |
1986 |
7.48 |
None |
Don't know WAC at introduction as product was purchased. Best estimate that has been provided is the original WAC under the Medicaid Drug Rebate Program which is from the 2nd quarter of 1992. |
| Rx0000205 |
Eyevance Pharmaceuticals LLC |
09/30/2021 |
00065064515 |
Natacyn (natamycin ophthalmic suspension 5.0%) 15mL Bottle Liquid |
08/03/2021 |
115.19 |
473.64 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/16/2019 |
Novartis AG |
None |
1 |
None |
329.17 |
310.54 |
1982 |
74.27 |
None |
Don't know WAC at introduction as product was purchased. Best estimate that has been provided is the original WAC under the Medicaid Drug Rebate Program which is from the 4th quarter of 1990. |
| Rx0000205 |
Eyevance Pharmaceuticals LLC |
09/30/2021 |
71776003505 |
TobraDex ST (tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05%) 5mL Bottle Liquid |
08/03/2021 |
11.33 |
237.90 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/16/2019 |
Novartis AG |
None |
1 |
None |
207.11 |
199.91 |
2009 |
85.80 |
None |
Don't know WAC at introduction as product was purchased. Best estimate that has been provided is the original WAC under the Medicaid Drug Rebate Program which is from the 4th quarter of 2010 |
| Rx0000063 |
Ferring Pharmaceuticals |
06/30/2021 |
55566280001 |
Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg) |
04/20/2021 |
21.76 |
456.99 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years. |
| Rx0000063 |
Ferring Pharmaceuticals |
12/31/2021 |
55566670001 |
CLENPIQ (sodium picosulfate/magnesium oxide/citric acid) Oral Solution 10 mg-3.5 gram-12 gra,160mL (bottle) |
12/30/2021 |
6.14 |
159.63 |
06/26/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000063 |
Ferring Pharmaceuticals |
03/31/2021 |
55566650003 |
Endometrin (progesterone) Dosage 100mg suppository (vaginal inserts) 21 inserts 21 applicators |
01/08/2021 |
10.59 |
275.26 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Ferring initially announced a higher price increase but implemented a lower price increase instead. |
| Rx0000063 |
Ferring Pharmaceuticals |
06/30/2021 |
55566750102 |
MENOPUR (menotropins for injection)/75 units/vial - 5 single-dose vials per package |
04/20/2021 |
41.90 |
1089.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note: The acquisition fields do not apply because Ferring did not acquire the product within the past five years.
NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price. " |
| Rx0000193 |
Forte Bio-Pharma, LLC |
06/30/2021 |
72245019310 |
Nalocet 2.5mg/300mg Tablet 100Ct |
05/01/2021 |
240.35 |
2643.85 |
None |
Non-innovator Multiple Source Drug |
4200 |
None |
Labor Costs- increase workforce of sales representatives |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000193 |
Forte Bio-Pharma, LLC |
06/30/2021 |
72245019303 |
Nalocet 2.5mg/300mg Tablet 30Ct |
05/01/2021 |
72.11 |
793.16 |
None |
Non-innovator Multiple Source Drug |
736 |
None |
Labor Costs- increase workforce of sales representatives |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000193 |
Forte Bio-Pharma, LLC |
06/30/2021 |
72245068310 |
Prolate 10mg/300mg Tablet 100ct |
05/01/2021 |
240.35 |
2643.85 |
None |
Non-innovator Multiple Source Drug |
6000 |
None |
Labor Costs- increase workforce of sales representatives |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000193 |
Forte Bio-Pharma, LLC |
06/30/2021 |
72245068110 |
Prolate 5mg/300mg Tablet 100ct |
05/01/2021 |
240.35 |
2643.85 |
None |
Non-innovator Multiple Source Drug |
1800 |
None |
Labor Costs- increase workforce of sales representatives |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000193 |
Forte Bio-Pharma, LLC |
06/30/2021 |
72245068210 |
Prolate 7.5mg/300mg Tablet 100ct |
05/01/2021 |
240.35 |
2643.85 |
None |
Non-innovator Multiple Source Drug |
1500 |
None |
Labor Costs- increase workforce of sales representatives |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2021 |
63323036005 |
1 Vial of 100 ML Intravenous Solution 10% |
12/29/2021 |
4.28 |
49.28 |
07/25/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2021 |
63323036061 |
20 Vials of 100 ML Intravenous Solution 10% |
12/29/2021 |
58.60 |
985.60 |
07/25/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2021 |
63323036059 |
25 Vials of 50 ML Intravenous Solution 10% |
12/29/2021 |
53.50 |
616.00 |
07/25/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000100 |
Fresenius Medical Care |
03/31/2021 |
49230064331 |
PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE |
01/01/2021 |
8.12 |
170.61 |
02/23/2030 |
Single Source Drug |
None |
1 |
The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information.
Fresenius Medical Care did not acquire Phoslyra in the prior five year period. |
| Rx0000100 |
Fresenius Medical Care |
03/31/2021 |
49230064551 |
VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE |
01/01/2021 |
68.74 |
1443.51 |
01/23/2030 |
Single Source Drug |
None |
1 |
The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information.
Fresenius Medical Care is the authorized distributor for Velphoro.
Fresenius Medical Care did not acquire Velphoro in the prior five year period. |
| Rx0000401 |
Galt Pharmaceuticals, LLC |
09/30/2021 |
61825030260 |
Orphengesic Forte (Orphenadrine Citrate 50 mg/Aspirin 770 mg/Caffeine 60 mg) Tablets, 60 Count |
08/01/2021 |
360.00 |
1950.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Galt Pharmaceuticals utilizes a proprietary revenue process which includes pricing. After maintaining consistent pricing since product launch, we were recently forced to implement a price increase. This increase included impact of Covid-19, supply chain shortages and the alarming inflationary pressures being seen across the country. Additionally to these macroeconomic factors are the significant increases in fees charged by PBMs and wholesalers to offset their own responses to the same. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000029 |
GlaxoSmithKline |
03/31/2021 |
58160081143 |
PEDIARIX 0.5ML Pre-filled Syringe; Dosage form: Injection; 1 Pack |
01/01/2021 |
7.13 |
90.05 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pricing provided reflects Federal Excise Tax. Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000029 |
GlaxoSmithKline |
03/31/2021 |
58160081152 |
PEDIARIX 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack |
01/01/2021 |
71.25 |
900.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pricing provided reflects Federal Excise Tax. Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
| Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639010501 |
AKYNZEO Intravenous Solution 235-0.25 MG/20ML |
07/01/2021 |
13.41 |
683.19 |
06/02/2037 |
Single Source Drug |
25000 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639010201 |
AKYNZEO Intravenous Solution Reconstituted 235MG/0.25MG PER VIAL |
07/01/2021 |
13.41 |
683.19 |
06/02/2037 |
Single Source Drug |
400 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000144 |
Helsinn Therapeutics, Inc |
09/30/2021 |
69639012001 |
VALCHLOR 0.016% Gel 60gm tube |
07/01/2021 |
318.91 |
4874.69 |
07/08/2029 |
Single Source Drug |
620 |
None |
The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. |
None |
n/a |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
03/31/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
01/01/2021 |
8.65 |
392.84 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
06/30/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial |
04/01/2021 |
8.84 |
401.68 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
09/30/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial; injectable emulsion |
07/01/2021 |
9.04 |
410.72 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000119 |
Heron Therapeutics, Inc. |
12/31/2021 |
47426020101 |
CINVANTI; 130 mg; single-dose vial; injectable emulsion |
10/01/2021 |
9.24 |
419.96 |
None |
Single Source Drug |
575739 |
None |
Increase due to market factors |
None |
There were no changes to the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143993125 |
Cefotaxime Sodium Injection Solution Reconstituted 1gm |
02/15/2021 |
10.45 |
65.45 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143993325 |
Cefotaxime Sodium Injection Solution Reconstituted 2gm |
02/15/2021 |
23.75 |
148.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
This product was previously removed from the market due to a discontinuation of the raw material we use from our supplier. Hikma had to reinvest in the product to find a new API supplier and R&D work to qualify and reintroduce the product. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143978710 |
Enalaprilat Intravenous Injection 1.25mg/mL, 1mL |
02/15/2021 |
4.35 |
48.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00143978610 |
Enalaprilat Intravenous Injection 1.25mg/mL, 2mL |
02/15/2021 |
7.77 |
86.28 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641602110 |
Famotidine Intravenous Solution 200mg/20mL |
02/15/2021 |
7.92 |
87.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641602325 |
Famotidine Intravenous Solution 40mg/4mL |
02/15/2021 |
5.58 |
61.90 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604610 |
Lorazepam Injection Solution 2mg/mL |
02/15/2021 |
9.59 |
106.46 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604710 |
Lorazepam Injection Solution 4mg/mL, 10mL |
02/15/2021 |
13.04 |
144.77 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
03/31/2021 |
00641604525 |
Lorazepam Injection Solution 4mg/mL, 1mL |
02/15/2021 |
6.36 |
70.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. Increase in cost of refrigeration and cold chain supply. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641094835 |
Promethazine HCl Injection Solution 25 MG/ML, Qty 25 |
10/01/2021 |
22.64 |
43.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641094935 |
Promethazine HCl Injection Solution 50mg/mL, 1mL, Qty 25 |
10/01/2021 |
16.64 |
62.89 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641095525 |
Promethazine Hydrochloride Solution Injection Solution 25 MG/ML, Qty 25 |
10/01/2021 |
22.14 |
43.64 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000178 |
Hikma Pharmaceuticals USA Inc |
12/31/2021 |
00641095625 |
Promethazine Hydrochloride Solution Injection Solution 50mg/mL, 1mL, Qty 25 |
10/01/2021 |
44.89 |
91.14 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
| Rx0000145 |
Horizon Therapeutics USA, Inc. |
03/31/2021 |
75987008010 |
Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial |
02/01/2021 |
1138.06 |
24847.56 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Columns left blank contain non-public information. Acquisition columns left blank because this product was not acquired within the last five years. |
| Rx0000040 |
Ingenus Pharmaceuticals, LLC |
03/31/2021 |
50742051530 |
Nitro-Dur Patch 0.3mg/hr 30 ct |
02/15/2021 |
235.52 |
1177.58 |
None |
Single Source Drug |
6255 |
None |
Increased overhead, expenses, and distribution costs causing need for price increase so as not to experience service disruption. |
None |
No changes made |
None |
08/31/2017 |
USPharma |
2000000 |
None |
The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure |
316.92 |
157.50 |
2017 |
316.92 |
None |
Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year |
| Rx0000040 |
Ingenus Pharmaceuticals, LLC |
03/31/2021 |
50742051830 |
Nitro-Dur Patch 0.8mg/hr 30 ct |
02/15/2021 |
255.44 |
1277.13 |
None |
Single Source Drug |
2585 |
None |
Increased overhead, expenses, and distribution costs causing need for price increase so as not to experience service disruption. |
None |
No changes made |
None |
08/13/2017 |
USPharma |
2000000 |
None |
The acquisition price provided was for the acquisition of the Nitro-Dur product line from USPharma and is not a SKU specific figure |
343.71 |
170.70 |
2017 |
343.71 |
None |
Patent expiration date: as this product is pre-patent, we do not have a patent expiration date to provide Year Introduced to Market: only the 0.3mg sold in 2017, the rest of the SKUs were first sold in 2018. However, we loaded all SKUs to the Gold Standard with 2017 effective dates. Therefore, we have listed 2017 as the introduction year |
| Rx0000287 |
Insmed Incorporated |
03/31/2021 |
71558059028 |
AMIKACIN LIPOSOME INHALATION SUSPENSION EQ 590MG BASE/8.4ML |
01/01/2021 |
755.69 |
12381.68 |
05/15/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Product developed in-house |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054104005 |
Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 4ml. |
01/12/2021 |
221.00 |
5127.00 |
03/11/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054004301 |
Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml. |
01/12/2021 |
106.00 |
2472.00 |
10/15/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/03/2017 |
Merrimack Pharmaceuticals |
None |
1 |
For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased the global oncology assets of Merrimack Pharmaceuticals in April 2017, including Onivyde. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of the assets from Merrimack Pharmaceuticals is available on p. 97, Note 12.1.1 of section 3.2.5, of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2018/03/15164935/IPSEN_DDR_2017_VA_complet_clean-003.pdf |
1652.40 |
None |
2015 |
1620.00 |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01 |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054112004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/12/2021 |
394.00 |
9150.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054112003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054106004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/12/2021 |
251.00 |
5826.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054106003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054109004 |
Drug product name: Somatuline Depot - New NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/12/2021 |
334.00 |
7759.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This NDC was launched on September 1, 2019 and will replace NDC 15054109003. The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054112003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 120 mg/0.5 ml. Drug product dosage form: syringe. Drug product package size: .50 ml. |
01/12/2021 |
394.00 |
9150.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054109003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 90 mg/0.3 ml. Drug product dosage form: syringe. Drug product package size: .30 ml. |
01/12/2021 |
334.00 |
7759.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
| Rx0000084 |
Ipsen Biopharmaceuticals, Inc. |
03/31/2021 |
15054106003 |
Drug product name: Somatuline Depot - Old NDC. Drug product strength: 60 mg/0.2 ml. Drug product dosage form: syringe. Drug product package size: .20 ml. |
01/12/2021 |
251.00 |
5826.00 |
03/08/2020 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
The product was not acquired by Ipsen within the previous five years. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894007101 |
SIMPONI® (golimumab) Prefilled Syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/15/2021 |
277.40 |
6056.66 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894007001 |
SIMPONI® (golimumab) Prefilled Syringe Strength:50mg/0.5mL Package Size:1 Form:1 Single syringe |
01/15/2021 |
241.22 |
5266.65 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894007102 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:100mg/1mL Package Size:1 Form:1 Single Autoinjector |
01/15/2021 |
277.40 |
6056.66 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894007002 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:50mg/0.5mL Package Size:1 Form:1 Single Autoinjector |
01/15/2021 |
241.22 |
5266.65 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894006003 |
STELARA® (ustekinumab) prefilled syringe Strength:45mg/0.5mL Package Size:1 Form:1 Single syringe |
01/15/2021 |
553.99 |
12095.41 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894006103 |
STELARA® (ustekinumab) prefilled syringe Strength:90mg/1mL Package Size:1 Form:1 Single syringe |
01/15/2021 |
1107.98 |
24190.82 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894006002 |
STELARA® (ustekinumab) vial Strength:45mg Package Size:1 Form:1 Single vial |
01/15/2021 |
553.99 |
12095.41 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000248 |
Janssen Biotech, Inc. |
03/31/2021 |
57894064001 |
TREMFYA™ (guselkumab) prefilled syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/15/2021 |
546.80 |
11938.37 |
01/18/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available, and includes pending patent term extension. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458056201 |
INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
67.33 |
1469.98 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458056301 |
INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
89.77 |
1960.05 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458056401 |
INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
134.66 |
2940.01 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458056001 |
INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
22.44 |
489.97 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458056101 |
INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
44.88 |
979.97 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458060601 |
INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
134.65 |
2939.91 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458060701 |
INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
202.00 |
4409.94 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458060801 |
INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
269.30 |
5880.15 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458060901 |
INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
403.99 |
8820.03 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458054360 |
INVOKAMET® Strength:150/1000 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458054260 |
INVOKAMET® Strength:150/500 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458054160 |
INVOKAMET® Strength:50/1000 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458054060 |
INVOKAMET® Strength:50/500 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458094301 |
INVOKAMET® XR Strength:150/1000 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458094201 |
INVOKAMET® XR Strength:150/500 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458094101 |
INVOKAMET® XR Strength:50/1000 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458094001 |
INVOKAMET® XR Strength:50/500 MG Package Size:60 Form:Tablet |
01/15/2021 |
24.89 |
543.43 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458014030 |
INVOKANA® Strength:100mg Package Size:30 Form:Tablet |
01/15/2021 |
24.90 |
543.43 |
05/11/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458014090 |
INVOKANA® Strength:100mg Package Size:90 Form:Tablet |
01/15/2021 |
74.67 |
1630.28 |
05/11/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458014130 |
INVOKANA® Strength:300mg Package Size:30 Form:Tablet |
01/15/2021 |
24.90 |
543.43 |
05/11/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458014190 |
INVOKANA® Strength:300mg Package Size:90 Form:Tablet |
01/15/2021 |
74.67 |
1630.28 |
05/11/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458030911 |
RISPERDAL® CONSTA® Strength:12.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
12.20 |
266.47 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2021. Patent expiration date was 11/25/2020 |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458030611 |
RISPERDAL® CONSTA® Strength:25 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
24.41 |
532.91 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. Patent expiration date was 11/25/2020 |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458030711 |
RISPERDAL® CONSTA® Strength:37.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
36.61 |
799.40 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. Patent expiration date was 11/25/2020 |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458030811 |
RISPERDAL® CONSTA® Strength:50 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/15/2021 |
48.82 |
1065.89 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. Patent expiration date was 11/25/2020 |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458058451 |
XARELTO Starter Pack™ Strength:15mg/20mg Package Size:51 Form:Tablet |
01/15/2021 |
38.35 |
837.25 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057710 |
XARELTO® Strength: 2.5 mg Package Size: 100 Form: Tablet |
01/15/2021 |
37.60 |
820.83 |
01/31/2039 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057718 |
XARELTO® Strength: 2.5 mg Package Size: 180 Form: Tablet |
01/15/2021 |
67.67 |
1477.48 |
01/31/2039 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057760 |
XARELTO® Strength: 2.5 mg Package Size: 60 Form: Tablet |
01/15/2021 |
22.56 |
492.50 |
01/31/2039 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458058010 |
XARELTO® Strength:10 mg Package Size:100 Form:Tablet |
01/15/2021 |
75.19 |
1641.65 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458058030 |
XARELTO® Strength:10 mg Package Size:30 Form:Tablet |
01/15/2021 |
22.56 |
492.50 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458058090 |
XARELTO® Strength:10 mg Package Size:90 Form:Tablet |
01/15/2021 |
67.67 |
1477.48 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057810 |
XARELTO® Strength:15 mg Package Size:100 Form:Tablet |
01/15/2021 |
75.19 |
1641.65 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057830 |
XARELTO® Strength:15 mg Package Size:30 Form:Tablet |
01/15/2021 |
22.56 |
492.50 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057890 |
XARELTO® Strength:15 mg Package Size:90 Form:Tablet |
01/15/2021 |
67.67 |
1477.48 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057910 |
XARELTO® Strength:20 mg Package Size:100 Form:Tablet |
01/15/2021 |
75.19 |
1641.65 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057930 |
XARELTO® Strength:20 mg Package Size:30 Form:Tablet |
01/15/2021 |
22.56 |
492.50 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000253 |
Janssen Pharmaceuticals, Inc. |
03/31/2021 |
50458057990 |
XARELTO® Strength:20 mg Package Size:90 Form:Tablet |
01/15/2021 |
67.67 |
1477.48 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676027801 |
EDURANT Strength:25 MG Package Size:30 Form:Tablet |
01/15/2021 |
52.44 |
1217.73 |
04/21/2025 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676060012 |
ERLEADA™ Strength: 60 mg Package Size:120 Form: Tablet |
01/15/2021 |
587.78 |
12833.26 |
04/30/2038 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676057530 |
PREZCOBIX™ (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet |
01/15/2021 |
90.82 |
2109.02 |
10/06/2032 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676056401 |
PREZISTA® Strength:150 MG Package Size:240 Form:Tablet |
01/15/2021 |
79.46 |
1845.19 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676056201 |
PREZISTA® Strength:600 MG Package Size:60 Form:Tablet |
01/15/2021 |
79.46 |
1845.19 |
06/26/2027 |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676056301 |
PREZISTA® Strength:75 MG Package Size:480 Form:Tablet |
01/15/2021 |
79.46 |
1845.19 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676056630 |
PREZISTA® Strength:800 MG Package Size:30 Form:Tablet |
01/15/2021 |
79.46 |
1845.19 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676056501 |
PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension |
01/15/2021 |
44.14 |
1025.04 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021 and includes 6 months of pediatric exclusivity. |
| Rx0000250 |
Janssen Products, LP |
03/31/2021 |
59676080030 |
SYMTUZA™ Strength: (darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) Package Size: 30 Form: Tablet |
01/15/2021 |
175.04 |
4064.80 |
07/19/2038 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021. |
| Rx0000008 |
Jazz Pharmaceuticals, Inc. |
03/31/2021 |
68727010001 |
Xyrem 500 MG/ML Oral Solution 180 ml |
01/07/2021 |
8.50 |
5544.48 |
09/15/2033 |
Single Source Drug |
1741758000 |
None |
None |
1 |
A change or improvement to the drug did not necessitate the price increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
The drug was not was acquired from another manufacturer within the last five years. |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2021 |
76125090001 |
GAMMAKED™ 1 g protein 10 mL |
05/02/2021 |
7.29 |
159.10 |
None |
Single Source Drug |
1 |
None |
Due to the rising cost of plasma collection and manufacturing, it is necessary for Kedrion to take a price increase on GAMMAKED |
None |
none |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This is an inner NDC-the vial. The individual vials are not sold as one vial, they are the vials inside the other ndcs which are packages of 5, 10 and 20 vials. I don’t think the website accepts zero so I put 1. |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2021 |
76125090010 |
GAMMAKED™ 10 g protein 100 mL |
05/02/2021 |
72.90 |
1591.00 |
None |
Single Source Drug |
52221 |
None |
Due to the rising cost of plasma collection and manufacturing, it is necessary for Kedrion to take a price increase on GAMMAKED |
None |
none |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2021 |
76125090020 |
GAMMAKED™ 20 g protein 200 mL |
05/02/2021 |
145.80 |
3182.00 |
None |
Single Source Drug |
67988 |
None |
Due to the rising cost of plasma collection and manufacturing, it is necessary for Kedrion to take a price increase on GAMMAKED |
None |
none |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000264 |
Kedrion Biopharma Inc. |
06/30/2021 |
76125090050 |
GAMMAKED™ 5 g protein 50 mL |
05/02/2021 |
36.45 |
795.50 |
None |
Single Source Drug |
26986 |
None |
Due to the rising cost of plasma collection and manufacturing, it is necessary for Kedrion to take a price increase on GAMMAKED |
None |
none |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000386 |
KVK Tech, Inc. |
06/30/2021 |
10702005501 |
HYDROCODONE BIT-HOMATROPINE METHYLBROMIDE TABLET 5MG/1.5MG 100 |
04/07/2021 |
37.55 |
115.00 |
None |
Non-innovator Multiple Source Drug |
120000 |
None |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last 5 years |
| Rx0000083 |
Laboratoire HRA Pharma |
03/31/2021 |
76336008060 |
Lysodren 500 mg tablets 100 count bottles |
02/15/2021 |
91.29 |
1013.39 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/15/2018 |
BMS |
None |
1 |
None |
479.95 |
479.95 |
1970 |
89.95 |
None |
Lysodren US rights acquired from BMS in March 2018. NDC changed from BMS to HRA Pharma in May 2019. Acquisition price is non-public information. WAC at acquisition from BMS in 2018 was $479.95. Introduced to market in 1970. |
| Rx0000083 |
Laboratoire HRA Pharma |
03/31/2021 |
76336045518 |
Metopirone 250 mg capsules 18 count bottles |
02/15/2021 |
52.22 |
579.72 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Metopirone sales and unit sales are non-public information. The product was acquired from Novartis in March 2011. The WAC at time of acquisition is unknown (2011). The product was introduced to the US in 1961. |
| Rx0000009 |
Lantheus Medical Imaging, Inc. |
03/31/2021 |
11994001104 |
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, one box four (4) vials |
01/01/2021 |
63.75 |
1126.27 |
03/16/2037 |
Single Source Drug |
None |
1 |
Increases are due to costs relating to raw material and labor expenses necessary for the manufacture and delivery of our Products. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not Applicable. This product was not acquired. |
| Rx0000009 |
Lantheus Medical Imaging, Inc. |
03/31/2021 |
11994001116 |
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, one box sixteen (16) vials |
01/01/2021 |
255.00 |
4505.06 |
03/16/2037 |
Single Source Drug |
None |
1 |
Increases are due to costs relating to raw material and labor expenses necessary for the manufacture and delivery of our Products. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not Applicable. This product was not acquired. |
| Rx0000317 |
LEADING PHARMA, LLC |
06/30/2021 |
69315023203 |
AMINOCAPROIC ACID 1000MG TABS 30 |
06/21/2021 |
294.65 |
1008.11 |
None |
Non-innovator Multiple Source Drug |
16142522 |
None |
Matching competitor |
None |
Remain competative |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50222030260 |
ENSTILAR AEROSOL FOAM, 1 CAN 60gm 0.005-0.064 % |
01/01/2021 |
55.67 |
1168.95 |
12/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50222030266 |
ENSTILAR AEROSOL FOAM, 2 CANS 120 gm 0.005-0.064 % |
01/01/2021 |
111.32 |
2337.88 |
12/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50222030350 |
FINACEA 15% FOAM 50GM CAN |
01/01/2021 |
18.28 |
383.84 |
02/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2015 |
255.01 |
None |
Market WAC effective 08/31/2015. We are reporting this NDC because it replaced the Bayer NDC 50419082901. The LEO NDC 50222030350 shares the same history as the Bayer NDC 50419082901. The market entry date for this LEO NDC 50222030350 was April 2020. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50419082901 |
FINACEA 15% FOAM 50GM CN |
01/01/2021 |
18.28 |
383.84 |
02/28/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/04/2018 |
Bayer Pharmaceuticals |
None |
1 |
None |
326.89 |
297.44 |
2015 |
255.01 |
None |
Market WAC effective 08/31/2015. Bayer NDC 50419082901 was replaced by LEO NDC 50222030350. LEO NDC 50222030350 entered market in April 2020 and uses the same history as Bayer NDC 50419082901. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50222050166 |
TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 120g |
01/01/2021 |
66.79 |
2293.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000276 |
LEO Pharma Inc. |
03/31/2021 |
50222050106 |
TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 60g |
01/01/2021 |
33.40 |
1146.68 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired and therefore the acquisition related fields are not applicable. We understand that California is able to publicly release data submitted as part of this report. LEO Pharma Inc. is not a publicly held company and does not file SEC-related documents like the 10-K. We do not make any revenue information available publicly as it is highly confidential and proprietary business data. There are no LEO Pharma Inc. revenue reports in the public domain. Because of this data restriction, we are unable to provide revenue numbers for our products. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386082019 |
Northera 100mg. 90 Capsules |
01/04/2021 |
265.92 |
3065.13 |
02/18/2021 |
Single Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386082119 |
Northera 200mg. 90 Capsules |
01/04/2021 |
531.85 |
6130.25 |
02/18/2021 |
Single Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386082219 |
Northera 300mg. 90 Capsules |
01/04/2021 |
797.77 |
9195.39 |
02/18/2021 |
Single Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386031401 |
Onfi 10mg. 100 Tablets |
01/04/2021 |
209.27 |
2412.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386031501 |
Onfi 20mg. 100 Tablets |
01/04/2021 |
418.54 |
4824.21 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386031321 |
Onfi Oral Suspension 2.5mg/mL 120mL Bottle |
01/04/2021 |
109.95 |
1267.35 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386011101 |
Sabril 500mg. 100 Tablets |
01/04/2021 |
1519.98 |
17519.82 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386021165 |
Sabril 500mg. 50 Packets 500mg. each |
01/04/2021 |
759.99 |
8759.92 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386042101 |
Xenazine 12.5mg. 112 Tablets |
01/04/2021 |
1466.68 |
16905.40 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000025 |
Lundbeck LLC |
03/31/2021 |
67386042201 |
Xenazine 25.0mg. 112 Tablets |
01/04/2021 |
2933.36 |
33810.81 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields not completed as product was not acquired in the last 5 years. |
| Rx0000297 |
MannKind Corporation |
12/31/2021 |
47918088018 |
AFREZZA INSULIN HUMAN INHL PWD 90X4UN/90X8UN |
10/04/2021 |
56.80 |
1192.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
12/31/2021 |
47918089818 |
AFREZZA INSULIN HUMAN INHL PWD 90X8UN/90X12UN |
10/04/2021 |
94.67 |
1988.10 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
12/31/2021 |
47918090218 |
AFREZZA INSULIN,HUMAN INHL PWD 4/8/12 UNIT |
10/04/2021 |
75.74 |
1590.49 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
12/31/2021 |
47918087890 |
AFREZZA INSULIN,HUMAN INHL PWD 90X 8UNITS |
10/04/2021 |
37.87 |
795.24 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000297 |
MannKind Corporation |
12/31/2021 |
47918089190 |
AFREZZA INSULIN,HUMAN INHL PWR 90X12UNIT |
10/04/2021 |
56.80 |
1192.86 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2021 |
68308025010 |
Erythromycin Base Oral Capsule Delayed Release Particles 250 MG 100 count |
10/01/2021 |
253.19 |
735.85 |
None |
Single Source Drug |
9600 |
None |
CHANGE IN MARKET DYNAMICS |
None |
NONE |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2021 |
51862029510 |
Fabior External Foam 0.1 % 100g Can |
02/01/2021 |
80.91 |
1236.85 |
02/24/2030 |
Single Source Drug |
7148 |
None |
Annual WAC increase. |
None |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
830.32 |
722.02 |
2014 |
607.76 |
None |
Product NDC at WAC Introduction in 2014 was 00145-0020-02. Product WAC Introduction for current 51862-0295-10 NDC was $830.32 on 03/17/2017. Unit Sales reported for calendar year 2020. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2021 |
51862029550 |
Fabior External Foam 0.1 % 50g Can |
02/01/2021 |
40.46 |
618.42 |
02/24/2030 |
Single Source Drug |
73750 |
None |
Annual WAC increase. |
None |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
415.16 |
361.01 |
2014 |
303.88 |
None |
Product NDC at WAC Introduction in 2014 was 00145-0020-03. Product WAC Introduction for current 51862-0295-50 NDC was $415.16 on 03/03/2017. Unit Sales reported for calendar year 2020. |
| Rx0000072 |
Mayne Pharma Inc |
12/31/2021 |
68308011501 |
Methamphetamine HCl Oral Tablet 5 MG 100 count |
10/01/2021 |
401.75 |
1615.52 |
None |
Non-innovator Multiple Source Drug |
10800 |
None |
CHANGE IN MARKET DYNAMICS |
None |
NONE |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2021 |
51862037612 |
Sorilux External Foam 0.005 % 120g Can |
02/01/2021 |
110.88 |
1694.85 |
05/07/2028 |
Single Source Drug |
2361 |
None |
Annual WAC increase. |
None |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
1240.18 |
1078.42 |
2012 |
650.00 |
None |
Product NDC at WAC Introduction in 2012 was 00145-2130-07. Product WAC Introduction for current 51862-0376-12 NDC was $1240.18 on 05/11/2017. Unit Sales reported for calendar year 2020. |
| Rx0000072 |
Mayne Pharma Inc |
03/31/2021 |
51862037660 |
Sorilux External Foam 0.005 % 60g Can |
02/01/2021 |
58.00 |
886.52 |
05/07/2028 |
Single Source Drug |
27947 |
None |
Annual WAC increase. |
None |
None |
None |
08/17/2016 |
GlaxoSmithKline LLC |
None |
1 |
None |
648.70 |
564.09 |
2012 |
340.00 |
None |
Product NDC at WAC Introduction in 2012 was 00145-2130-06. Product WAC Introduction for current 51862-0376-60 NDC was $648.7 on 05/11/2017. Unit Sales reported for calendar year 2020. |
| Rx0000072 |
Mayne Pharma Inc |
09/30/2021 |
51862048601 |
TRIMETHOPRIM 100MG TABLETS 100 |
09/08/2021 |
93.15 |
186.30 |
None |
Non-innovator Multiple Source Drug |
236488 |
None |
change in market dynamics |
None |
NONE |
None |
08/03/2016 |
ALLERGAN |
652000000 |
None |
Trimethoprim was acquired as part of a portfolio of drugs from Allergan and Teva with at a total cost of $652 million. |
31.05 |
31.05 |
2001 |
20.70 |
None |
None |
| Rx0000378 |
Medicure Pharma, Inc. |
06/30/2021 |
25208000305 |
Sodium Nitroprusside 50 mg/2mL vial |
05/26/2021 |
35.00 |
50.00 |
01/01/2017 |
Non-innovator Multiple Source Drug |
9867 |
None |
Medicure takes multiple factors into consideration to determine the price of pharmaceutical products. These factors include; acquisition or development cost, market dynamics and discounts provided to government and commercial customers. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The WAC price was lowered on December 2, 2019 from $50 to $15 and then increased on April 26th from $15 to $50. The product was acquired before it was released into the market |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
03/31/2021 |
43538044060 |
Nicadan, 800-10-100, TAB, 60 EA |
02/26/2021 |
20.85 |
484.02 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000202 |
Medimetriks Pharmaceuticals, Inc |
06/30/2021 |
43538044060 |
Nicadan, 800-10-100, TAB, 60 EA |
05/06/2021 |
17.42 |
501.44 |
None |
Single Source Drug |
None |
1 |
Increase in operating costs, inflation, changes in the market |
None |
No changes or improvements were made to this drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This product was not acquired within the last 5 years |
| Rx0000382 |
Melinta Therapeutics, LLC |
09/30/2021 |
70842016010 |
MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (1mg dose) |
07/01/2021 |
135.89 |
2071.00 |
05/12/2031 |
Single Source Drug |
None |
1 |
Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors.
Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary. |
None |
None - see cost increase factors statement. |
None |
01/05/2018 |
The Medicines Company |
None |
1 |
None |
1544.13 |
1544.13 |
2015 |
1470.60 |
None |
None |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006412102 |
GARDASIL 9 0.5 mL Syringes 10 |
08/12/2021 |
143.12 |
2528.52 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006411903 |
GARDASIL 9 0.5 mL Vials 10 |
08/12/2021 |
143.12 |
2528.52 |
12/10/2028 |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006468100 |
M-M-R II 0.5 mL Vials 10 |
08/12/2021 |
48.15 |
850.64 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006483703 |
PNEUMOVAX 23 0.5 mL Syringes 10 |
08/12/2021 |
66.27 |
1170.81 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006494300 |
PNEUMOVAX 23 0.5 mL Vials 10 |
08/12/2021 |
66.27 |
1170.81 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006417100 |
PROQUAD 0.5 mL Vials 10 |
08/12/2021 |
139.82 |
2470.16 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000138 |
Merck & Co., Inc. |
09/30/2021 |
00006482700 |
VARIVAX 0.5 mL Vials 10 |
08/12/2021 |
85.03 |
1502.27 |
None |
Single Source Drug |
None |
1 |
Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines.
In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding:
• capital investments in the U.S. of more than $6 billion in the last three years, with planned investment of >$10 billion in the U.S. between 2020 and 2024 to increase manufacturing capacity
• investments in research and development that last year alone totaled nearly $13.6 billion ($103 billion since 2010), on a GAAP basis, focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people.
Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; Pursuant to the OSHPD User Manual, Merck has included a value of "1" in all public indicator columns when the requested information is not in the public domain or publicly available; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2021 |
72495020105 |
FEMRING 0.05MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE |
01/01/2021 |
49.96 |
581.45 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
485.37 |
443.67 |
2003 |
76.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2021 |
72495020210 |
FEMRING 0.10MG/DAY (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGEG |
01/01/2021 |
53.24 |
619.61 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
05/18/2018 |
Allergan |
None |
1 |
None |
517.23 |
472.79 |
2003 |
81.50 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
09/30/2021 |
72495040128 |
INTRAROSA 6.5mg/DAY (28 PRASTERONE INSERTS) FOR 28 DAYS USAGE |
08/16/2021 |
7.43 |
226.10 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/26/2020 |
AMAG |
None |
1 |
None |
212.30 |
202.00 |
2017 |
175.00 |
None |
Original NDC was changed from 64011060128 (AMAG) to 72495040128 (Millicent) in Q1 2021. Historical pricing from the AMAG NDC will be included in the history of the new Millicent NDC. |
| Rx0000051 |
MILLICENT U.S., INC. |
03/31/2021 |
64011060128 |
INTRAROSA 6.5mg/DAY (PRASTERONE INSERTS) 28 INSERTS FOR 28 DAYS USAGE |
01/01/2021 |
6.37 |
218.67 |
03/19/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/26/2020 |
AMAG |
None |
1 |
None |
212.30 |
202.00 |
2017 |
175.00 |
None |
None |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2021 |
67457022005 |
Isosulfan Blue 1% 50mg/5mL Liq 6s SUV |
07/01/2021 |
303.11 |
6365.34 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1)FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (2) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan Inc. |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2021 |
67457025905 |
Isosulfan Blue N+ 1% 50mg/5mL Liq 6s SUV |
07/01/2021 |
303.11 |
6365.34 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1)FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (2) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan Inc. |
| Rx0000044 |
Mylan Institutional Inc |
09/30/2021 |
67457058605 |
Isosulfan Blue PRX 1% 50mg/5mL Liq 6s SUV |
07/01/2021 |
303.11 |
6365.34 |
12/15/2028 |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1)FDA publishes, in the Orange Book, patent information for drugs approved under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FFDCA) as a NDA. Mylan’s product was approved under section 505(j) of the FFDCA as an ANDA. (2) Mylan Institutional Inc. owns and sells the product through Mylan Institutional LLC, and the product has been owned and sold by Mylan Institutional LLC for the past five years. Mylan Institutional Inc. and Mylan Institutional LLC are both indirectly wholly-owned subsidiaries of Mylan Inc. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165002030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 12.5 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165002530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 15.7 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165003030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 18.8 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165000530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 3.1 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165001030 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 6.3 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165001530 |
Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 9.4 MG |
01/09/2021 |
39.60 |
435.60 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165020030 |
COTEMPLA XR-ODT 17.3MG 30 Tabs/Bottle |
01/09/2021 |
25.20 |
445.20 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165030030 |
COTEMPLA XR-ODT 25.9MG 30 Tabs/Bottle |
01/09/2021 |
25.20 |
445.20 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000106 |
Neos Therapeutics, Inc. |
03/31/2021 |
70165010030 |
COTEMPLA XR-ODT 8.6MG, 30 Tabs/Bottle |
01/09/2021 |
25.20 |
445.20 |
06/28/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer. |
| Rx0000418 |
Nexus Pharmaceuticals, Inc. |
12/31/2021 |
14789090110 |
Procainamide HCL 100mg 10mL pack of 10 |
10/18/2021 |
1056.30 |
3000.00 |
None |
Non-innovator Multiple Source Drug |
6270 |
None |
Nexus considers multiple factors in determining ongoing pricing of their prescription drugs including value provided to patients, patient populations and changing market and competitive conditions. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000420 |
Nielsen BioSciences, Inc. |
06/30/2021 |
59584013801 |
Candin Skin Test Antigen liquid 1U/0.1mL 1.0mL |
04/01/2021 |
18.00 |
243.00 |
None |
Single Source Drug |
22942 |
None |
When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000420 |
Nielsen BioSciences, Inc. |
06/30/2021 |
59584014001 |
Spherusol Skin Test Antigen liquid 1.27mg/0.1mL 1.0mL |
05/01/2021 |
68.00 |
918.00 |
None |
Single Source Drug |
1818 |
None |
When pricing its products Nielsen takes into consideration multiple factors - including but not limited to: research and development (or asset acquisition) investments including required royalties; regulatory compliance fees and costs; manufacturing costs; discounts fees and other expenses associated with distribution and to facilitate patient access to the product; competition; general economic conditions and trends including inflation rates; the clinical and economic value of the product; and overall corporate business goals. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839015030 |
TEKTURNA 150MG TAB 30/EA |
01/15/2021 |
20.20 |
244.62 |
02/19/2026 |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
150.19 |
136.66 |
2011 |
81.98 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839030030 |
TEKTURNA 300MG TAB 30/EA |
01/15/2021 |
25.48 |
308.61 |
02/19/2026 |
Innovator Multiple Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
189.48 |
172.41 |
2011 |
103.42 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839011230 |
TEKTURNA HCT 150/12.5MG TAB 30/EA |
01/15/2021 |
20.20 |
244.62 |
07/13/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
150.19 |
136.66 |
2011 |
81.98 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839012530 |
TEKTURNA HCT 150/25MG TAB 30/EA |
01/15/2021 |
20.20 |
244.62 |
07/13/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
150.19 |
136.66 |
2011 |
81.98 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839031230 |
TEKTURNA HCT 300/12.5MG TAB 30/EA |
01/15/2021 |
25.48 |
308.61 |
07/13/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
189.48 |
172.41 |
2011 |
103.42 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000204 |
Noden Pharma USA, Inc. |
03/31/2021 |
70839032530 |
TEKTURNA HCT 300/25MG TAB 30/EA |
01/15/2021 |
25.48 |
308.61 |
07/13/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
07/01/2016 |
Novartis |
None |
1 |
None |
189.48 |
172.41 |
2011 |
103.42 |
None |
Acquired less than 5 years ago - WAC at intro to market was by NVS |
| Rx0000073 |
Novartis |
03/31/2021 |
00065027510 |
Azopt 1% Drops 10mL, 10pk, 1 dropper bottle |
01/06/2021 |
17.89 |
343.23 |
07/02/2017 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00065027515 |
Azopt 1% Drops 15mL, 15pk, 1 dropper bottle |
01/06/2021 |
26.84 |
514.80 |
07/02/2017 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078063968 |
Cosentyx 150mg/ml, pen, 1 Sensoready Pen |
01/06/2021 |
387.90 |
5929.33 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078063941 |
Cosentyx 150mg/ml, pen, 2 Sensoready Pens |
01/06/2021 |
387.90 |
5929.33 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078063997 |
Cosentyx 150mg/ml, syringe, 1 Syringe |
01/06/2021 |
387.90 |
5929.33 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078063998 |
Cosentyx 150mg/ml, syringe, 2 Syringes |
01/06/2021 |
387.90 |
5929.33 |
05/05/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00065924007 |
DUREZOL 0.05% 5mL, Drops, 5pk, 1 dropper bottle |
01/06/2021 |
10.82 |
207.62 |
11/18/2019 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078065967 |
Entresto 24/26mg - Tabs, 180 Each Bottle, 1 bottle |
01/06/2021 |
114.40 |
1748.68 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078065920 |
Entresto 24/26mg - Tabs, 60 Each Bottle, 1 bottle |
01/06/2021 |
38.13 |
582.89 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078077767 |
Entresto 49/51mg - Tabs, 180 Each Bottle, 1 bottle |
01/06/2021 |
114.40 |
1748.68 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078077720 |
Entresto 49/51mg - Tabs, 60 Each Bottle, 1 bottle |
01/06/2021 |
38.13 |
582.89 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078069667 |
Entresto 97/103mg - Tabs, 180 Each Bottle, 1 bottle |
01/06/2021 |
114.40 |
1748.68 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078069620 |
Entresto 97/103mg - Tabs, 60 Each Bottle, 1 bottle |
01/06/2021 |
38.13 |
582.89 |
08/22/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00065175014 |
Ilevro 0.3%, Drops, 3mL per bottle, 1 bottle |
01/06/2021 |
15.96 |
306.17 |
03/31/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078086001 |
KISQALI 200mg daily dose, 1 blister pack x 21 tablets (21 tablets per carton) |
01/06/2021 |
370.81 |
5668.15 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078086742 |
KISQALI 400mg daily dose, 3 blister packs x 14 tablets (42 tablets per carton) |
01/06/2021 |
741.63 |
11336.34 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078087463 |
KISQALI 600mg daily dose, 3 blister packs x 21 tablets (63 tablets per carton) |
01/06/2021 |
927.04 |
14170.42 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078090961 |
KISQALI FEMARA CO-PACK, Kisqali 1 blister pack, containing 21 tablets 200mg per tablet, Femara 2.5mg 28s |
01/06/2021 |
370.81 |
5668.15 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078091661 |
KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily |
01/06/2021 |
741.63 |
11336.34 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078092361 |
KISQALI FEMARA CO-PACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s |
01/06/2021 |
927.04 |
14170.42 |
04/14/2036 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078066615 |
Mekinist 0.5 mg 30 tabs per bottle, 1 bottle |
01/06/2021 |
193.01 |
3702.29 |
01/28/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078066815 |
Mekinist 2 mg 30 tabs per bottle, 1 bottle |
01/06/2021 |
656.91 |
12600.79 |
01/28/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068415 |
Promacta 12.5 mg, 30 tabs per bottle, 1 bottle |
01/06/2021 |
368.99 |
5640.31 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068515 |
Promacta 25 mg, 30 tabs per bottle, 1 bottle |
01/06/2021 |
368.99 |
5640.31 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068615 |
Promacta 50 mg, 30 tabs per bottle, 1 bottle |
01/06/2021 |
667.76 |
10207.17 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068715 |
Promacta 75 mg, 30 tabs per bottle, 1 bottle |
01/06/2021 |
1001.64 |
15310.76 |
02/01/2028 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078069819 |
Rydapt 25 mg, 112 tabs per bottle, 1 bottle |
01/06/2021 |
986.52 |
18923.27 |
12/02/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078069899 |
Rydapt 25 mg, 56 tabs per bottle, 1 bottle |
01/06/2021 |
493.26 |
9461.64 |
12/02/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00065414727 |
SIMBRINZA 1% / 0.2%, Drops, 8mL per bottle, 1 bottle |
01/06/2021 |
9.44 |
181.12 |
10/30/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Product was on the market at the time of the acquisition. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068266 |
Tafinlar 50 mg, 120 tabs per bottle, 1 bottle |
01/06/2021 |
469.48 |
9005.53 |
10/15/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078068166 |
Tafinlar 75 mg, 120 tabs per bottle, 1 bottle |
01/06/2021 |
605.05 |
11605.88 |
10/15/2030 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078059287 |
Tasigna 150mg, 28 capsule per bottle, 4 bottles |
01/06/2021 |
1030.12 |
15746.14 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078052687 |
Tasigna 200mg, 28 capsule per bottle, 4 bottles |
01/06/2021 |
1030.12 |
15746.14 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078095166 |
Tasigna 50mg, 120 capsule per bottle, 1 bottle |
01/06/2021 |
1103.70 |
16870.81 |
10/07/2032 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078067066 |
Votrient 200 mg 120 tabs per bottle, 1 bottle |
01/06/2021 |
758.88 |
14556.72 |
10/19/2023 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period. |
| Rx0000073 |
Novartis |
03/31/2021 |
00078091112 |
XIIDRA 5% 50 mg/mL 60-count carton, 12 pouches of 5 single-use containers (0.2mL each) |
01/06/2021 |
38.75 |
592.29 |
07/25/2033 |
Single Source Drug |
None |
1 |
Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics |
None |
Not applicable |
None |
05/09/2019 |
Takeda Pharmaceutical Company Limited |
3400000000 |
None |
Novartis will pay $3.4 billion upfront, plus potential milestone payments of up to $1.9 billion. |
553.54 |
2019.00 |
2016 |
426.73 |
None |
All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. |
| Rx0000033 |
Novo |
03/31/2021 |
00169770521 |
Norditropin FlexPro Subcutaneous Solution Pen-injector 10 MG/1.5ML - 1 syringe in 1 carton |
01/15/2021 |
65.34 |
1398.74 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169770821 |
Norditropin FlexPro Subcutaneous Solution Pen-injector 15 MG/1.5ML - 1 syringe in 1 carton |
01/15/2021 |
98.00 |
2098.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169770321 |
Norditropin FlexPro Subcutaneous Solution Pen-injector 30 MG/3ML - 1 syringe in 1 carton |
01/15/2021 |
196.01 |
4196.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169770421 |
Norditropin FlexPro Subcutaneous Solution Pen-injector 5 MG/1.5ML - 1 syringe in 1 carton |
01/15/2021 |
32.67 |
699.37 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Norditropin is no longer under patent. NNI is the original manufacturer of Norditropin and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169413212 |
Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML - 1 syringe in 1 carton |
01/15/2021 |
40.55 |
851.60 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169413602 |
Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML - 2 syringes in 1 carton |
01/15/2021 |
40.55 |
851.60 |
06/21/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169406013 |
Victoza Subcutaneous Solution Pen-injector 6mg/mL 3x3mL - 3 syringes in 1 carton |
01/15/2021 |
48.39 |
1016.25 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |
| Rx0000033 |
Novo |
03/31/2021 |
00169406012 |
Victoza Subcutaneous Solution Pen-injector Victoza 6mg/mL 2x3mL - 2 syringes in 1 carton |
01/15/2021 |
32.26 |
677.50 |
07/09/2037 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
NNI holds a number of patents related to Victoza. We included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company. |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085003 |
Octagam 10% Vial 100Ml/10g |
10/01/2021 |
69.00 |
1796.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=575, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=584 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085004 |
Octagam 10% Vial 200Ml/20g |
10/01/2021 |
138.00 |
3592.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=576, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=585 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085001 |
Octagam 10% Vial 20Ml/2g |
10/01/2021 |
13.80 |
359.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=573, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=582 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085005 |
Octagam 10% Vial 300Ml/30g |
10/01/2021 |
207.00 |
5388.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=577, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=586 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982085002 |
Octagam 10% Vial 50Ml/5g |
10/01/2021 |
34.50 |
898.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=574, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=583 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084001 |
Octagam 5% Vial /1g |
10/01/2021 |
6.90 |
179.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=569, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=578 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084003 |
Octagam 5% Vial 100Ml/5g |
10/01/2021 |
34.50 |
898.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=571, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=580 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084004 |
Octagam 5% Vial 200Ml/10g |
10/01/2021 |
69.00 |
1796.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=572, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=581 |
None |
| Rx0000249 |
Octapharma USA, Inc. |
12/31/2021 |
68982084002 |
Octagam 5% Vial 50Ml/2.5g |
10/01/2021 |
17.25 |
449.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
"Increases in US source plasma costs and manufacturing costs
resulted in the price increase for the product." |
None |
"No change or improvement to the product necessitated the price increase.
Please refer to Cost Increase Factor statement" |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=570, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=579 |
None |
| Rx0000234 |
Optinose US, Inc. |
03/31/2021 |
71143037501 |
Fluticasone Propionate (Nasal) 93 MCG/ACT Exhaler Suspension, 1 Exhaler of 16 ML |
01/01/2021 |
28.34 |
542.97 |
07/07/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008213 |
JYNARQUE® (tolvaptan) 15 mg tablets, bottle of 30 |
01/15/2021 |
563.43 |
8612.44 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148007928 |
JYNARQUE® (tolvaptan) 15 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008313 |
JYNARQUE® (tolvaptan) 30 mg, bottle of 30 |
01/15/2021 |
563.43 |
8612.44 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008028 |
JYNARQUE® (tolvaptan) 30 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008728 |
JYNARQUE® (tolvaptan) 45 mg/15 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008828 |
JYNARQUE® (tolvaptan) 60 mg/30 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148008928 |
JYNARQUE® (tolvaptan) 90 mg/30 mg tablets, 4 x 14 weekly blister packs |
01/15/2021 |
1051.74 |
16076.56 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
JYNARQUE® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148002050 |
SAMSCA® (tolvaptan) 15 mg tablets, blister pack of 10 |
01/15/2021 |
247.71 |
5201.97 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
SAMSCA® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2021 |
59148002150 |
SAMSCA® (tolvaptan) 30 mg tablets, blister pack of 10 |
01/15/2021 |
256.97 |
5396.43 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
SAMSCA® is protected by an additional patent listed in FDA Orange Book with an expiration date of 9/1/2026. |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2021 |
69102013710 |
Lamotrigine USP Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets |
03/01/2021 |
31.00 |
648.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2021 |
69102030001 |
Subvenite (lamotrigine USP) Orange Starter Kit, (42) 25mg Tablets & (7) 100mg Tablets |
03/01/2021 |
31.00 |
648.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
67979051143 |
Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial |
10/01/2021 |
68.72 |
1485.55 |
05/08/2027 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 7/15/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
67979000101 |
Valstar, 40 mg/1ml solution, 4x5mL |
10/01/2021 |
339.85 |
7347.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/15/2021, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023016410 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 10 VL |
02/04/2021 |
148.17 |
2123.77 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023016425 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 25 VL |
02/04/2021 |
370.43 |
5309.43 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2021 |
42023019001 |
Vasostrict, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 10 mL |
02/04/2021 |
148.17 |
2123.77 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of 4/19/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the ?Patent Expiration Date? field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
12/31/2021 |
66887000301 |
Xiaflex, 0.9mg powder for solution, single use vial |
10/01/2021 |
204.12 |
5438.01 |
None |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration?s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank. (3) For ?Year Introduced?, Endo is providing the year in which first price point is published in the pricing compendia database for the labeler code / product / product presentation. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005197105 |
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) Injection Rx, 0.5 mL Prefilled Syringe, Pack Size 1 |
01/01/2021 |
10.17 |
217.74 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005197102 |
Prevnar 13 (pneumococcal 13-valent conjugate vaccine) Injection Rx, 0.5 mL Prefilled Syringe, Pack Size 10 |
01/01/2021 |
98.61 |
2111.14 |
11/09/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005010010 |
Trumenba (meningococcal group B vaccine) Injection Rx, 120 mcg/0.5 mL Prefilled Syringe, Pack Size 10 |
01/01/2021 |
74.57 |
1565.99 |
08/27/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00005010005 |
Trumenba (meningococcal group B vaccine) Injection Rx, 120 mcg/0.5 mL Prefilled Syringe, Pack Size 5 |
01/01/2021 |
37.29 |
783.00 |
08/27/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069100201 |
Xeljanz (tofacitinib), 10 mg Tablet, 60ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069100101 |
Xeljanz (tofacitinib), 5 mg Tablet, 60ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000006 |
Pfizer |
03/31/2021 |
00069050130 |
Xeljanz XR (tofacitinib), 11mg Tablet, 30ct |
01/01/2021 |
230.31 |
4930.49 |
12/08/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions.
(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available.
(2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years.
(3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website. |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014012 |
IMBRUVICA(ibrutinib); 140mg capsule; 120 ct |
01/01/2021 |
1370.70 |
19893.69 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014009 |
IMBRUVICA(ibrutinib); 140mg capsule; 90 ct |
01/01/2021 |
1028.03 |
14920.27 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962014028 |
IMBRUVICA(ibrutinib); 140mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962028028 |
IMBRUVICA(ibrutinib); 280mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962056028 |
IMBRUVICA(ibrutinib); 560mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962007028 |
IMBRUVICA(ibrutinib); 70mg capsules; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2021 |
57962042028 |
IMBRUVICA(ibrutinib);420mg tablets; 28 ct |
01/01/2021 |
959.49 |
13925.59 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
01/18/2021 |
346.74 |
5764.56 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
We took a 6.4% price increase vs. August and this calculates to the correct amount submitted to MediSpan |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
08/01/2021 |
172.94 |
5937.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
01/18/2021 |
253.81 |
4219.51 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
08/01/2021 |
126.59 |
4346.10 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
01/18/2021 |
577.93 |
9608.09 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
08/01/2021 |
288.24 |
9896.34 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
01/18/2021 |
644.01 |
10706.66 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
We took a 6.4% price increase vs. August and this calculates to the correct amount submitted to MediSpan |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
08/01/2021 |
749.47 |
11456.13 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2021 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
01/18/2021 |
385.26 |
6404.91 |
02/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2021 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
08/01/2021 |
192.15 |
6597.05 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
None |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Price increase for all strengths only includes PTC NCD related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market. |
| Rx0000220 |
Puma Biotechnology, Inc. |
03/31/2021 |
70437024018 |
Nerlynx Oral Tablet 40 mg, 180 tablet package |
01/15/2021 |
820.00 |
17515.00 |
12/31/2025 |
Single Source Drug |
14959 |
None |
A number of factors go into the pricing of NERLYNX including manufacturing, sales and marketing costs, and investments in continued research and development. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000220 |
Puma Biotechnology, Inc. |
09/30/2021 |
70437024018 |
Nerlynx Oral Tablet 40 mg, 180 tablet package |
08/01/2021 |
860.00 |
18375.00 |
07/18/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000324 |
PuraCap Labortories LLC dba Blu Pharmaceuticals |
09/30/2021 |
24658077005 |
Sulindac 150mg USP Tabs 500ct Blu |
07/01/2021 |
470.84 |
530.84 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Puracap developed the products |
| Rx0000324 |
PuraCap Labortories LLC dba Blu Pharmaceuticals |
09/30/2021 |
24658077105 |
Sulindac 200mg USP Tabs 500ct Blu |
07/01/2021 |
693.70 |
774.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market Dynamic Change |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Puracap developed the products |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075104 |
BUTRANS 10MCG/HOUR TDS 4S |
01/01/2021 |
23.15 |
486.13 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075804 |
BUTRANS 15 MCG/HOUR TDS 4S |
01/01/2021 |
33.39 |
701.23 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075204 |
BUTRANS 20MCG/HOUR TDS 4S |
01/01/2021 |
40.98 |
860.61 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075004 |
BUTRANS 5 MCG/HOUR TDS 4S |
01/01/2021 |
15.43 |
324.08 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011075704 |
BUTRANS 7.5 MCG/HOUR TDS 4S |
01/01/2021 |
21.61 |
453.71 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027660 |
HYSINGLA ER 100MG TABLETS 60S |
01/01/2021 |
138.98 |
2918.65 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027760 |
HYSINGLA ER 120MG TABLETS 60S |
01/01/2021 |
154.02 |
3234.39 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027160 |
HYSINGLA ER 20MG TABLETS 60S |
01/01/2021 |
29.75 |
624.82 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027260 |
HYSINGLA ER 30MG TABLETS 60S |
01/01/2021 |
43.43 |
912.02 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027360 |
HYSINGLA ER 40MG TABLETS 60S |
01/01/2021 |
58.51 |
1228.70 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027460 |
HYSINGLA ER 60MG TABLETS 60S |
01/01/2021 |
81.02 |
1701.36 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011027560 |
HYSINGLA ER 80MG TABLETS 60S |
01/01/2021 |
109.23 |
2293.84 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041010 |
OXYCONTIN 10MG TABLETS 100S |
01/01/2021 |
21.13 |
443.71 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041020 |
OXYCONTIN 10MG TABLETS HUD 20S |
01/01/2021 |
4.34 |
91.11 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041510 |
OXYCONTIN 15MG TABLETS 100S |
01/01/2021 |
31.11 |
653.22 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011041520 |
OXYCONTIN 15MG TABLETS HUD 20S |
01/01/2021 |
6.38 |
134.02 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011042010 |
OXYCONTIN 20MG TABLETS 100S |
01/01/2021 |
39.41 |
827.51 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011042020 |
OXYCONTIN 20MG TABLETS HUD 20S |
01/01/2021 |
8.08 |
169.74 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011043010 |
OXYCONTIN 30MG TABLETS 100S |
01/01/2021 |
54.80 |
1150.85 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011043020 |
OXYCONTIN 30MG TABLETS HUD 20S |
01/01/2021 |
11.24 |
236.12 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011044010 |
OXYCONTIN 40MG TABLETS 100S |
01/01/2021 |
67.49 |
1417.19 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011044020 |
OXYCONTIN 40MG TABLETS HUD 20S |
01/01/2021 |
13.84 |
290.59 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011046010 |
OXYCONTIN 60MG TABLETS 100S |
01/01/2021 |
95.55 |
2006.51 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011046020 |
OXYCONTIN 60MG TABLETS HUD 20S |
01/01/2021 |
19.60 |
411.65 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011048010 |
OXYCONTIN 80MG TABLETS 100S |
01/01/2021 |
117.76 |
2472.94 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000056 |
Purdue Pharma LP |
03/31/2021 |
59011048020 |
OXYCONTIN 80MG TABLETS HUD 20S |
01/01/2021 |
24.16 |
507.29 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health. |
| Rx0000342 |
PureTek Corporation |
09/30/2021 |
59088075900 |
Empricaine II, Lidocaine2.5%/Prilocaine 2.5% cream USP, 30 g + Occlusive Dressing, 6cm x 7cm, Sterile,Trans.w/frame in pouch |
09/17/2021 |
560.02 |
1820.00 |
None |
Single Source Drug |
98 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000356 |
Radius Health, Inc. |
03/31/2021 |
70539000101 |
TYMLOS 80 MCG Pen |
01/01/2021 |
155.34 |
2121.72 |
04/28/2031 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/29/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000356 |
Radius Health, Inc. |
03/31/2021 |
70539000102 |
TYMLOS 80 MCG Pen / Carton |
01/01/2021 |
155.34 |
2121.72 |
04/28/2031 |
Single Source Drug |
None |
1 |
Radius generally makes decisions on price revisions annually based on market conditions and corporate strategy, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients.
Radius takes into account several market and business considerations when setting a list price for a product, including, but not limited to:
- The clinical and health outcomes value of our products to patients and payors.
- Not only the budget impact to payers but also patient out of pocket costs to ensure that products reach the patients who need them.
- Responsible and competitive prices, in line with current treatment costs where other treatment options exist.
- Corporate business strategy, including costs and profitability.
- Consideration of other factors such as Annual CPI-U rates.
- R&D investment priorities and budgets to identify future medicines to improve the lives of patients
- Radius does not maintain records that reflect how these factors were applied in the context of any particular product or price increase. |
None |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 04/29/2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292020111 |
Chemet 100mg, 100 capsules, 1 bottle |
01/06/2021 |
152.67 |
2061.06 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
Manufacturing changes contributed to increasing the WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292081155 |
Cosmegen Inj 0.5mg, 1 vial |
01/06/2021 |
204.43 |
2248.68 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292010401 |
Desoxyn 5mg, 100 tabs, 1 bottle |
01/06/2021 |
170.17 |
1871.89 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
52292012252 |
NeoProfen Inj 2ml vial, 3 vials |
01/06/2021 |
243.87 |
2682.52 |
03/02/2032 |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000363 |
Recordati Rare Diseases, inc. |
03/31/2021 |
55292030401 |
Tranxene 7.5 mg, 100 tabs, 1 bottle |
01/06/2021 |
118.60 |
1304.58 |
None |
Single Source Drug |
None |
1 |
Increases of distribution, active pharmaceutical ingredients, marketing, and pharmacovigilance costs necessitate increasing our WAC price. |
None |
No changes/ improvements were made to this drug necessitating increasing our WAC price. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000166 |
Redhill Biopharma, Inc. |
03/31/2021 |
71068000110 |
AEMCOLO (rifamycin sodium) 12 194mg Oral Tablets |
01/01/2021 |
5.13 |
176.37 |
05/03/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
10/18/2019 |
Cosmo Technologies |
None |
1 |
Please see Supporting Docs for full Press Release details.
RedHill did not purchase the product from Cosmo, but instead Cosmo purchased 1,714,286 ADS at an agreed value of $12 million as an upfront payment, plus the ADS as part of the 36.3 million investment into RedHill. |
157.00 |
144.00 |
2018 |
144.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=470 |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2021 |
71332000101 |
Tavalisse 100 mg oral tablet 60 count |
06/29/2021 |
590.00 |
12400.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000239 |
Rigel Pharmaceuticals, Inc. |
06/30/2021 |
71332000201 |
Tavalisse 150 mg oral tablet 60 count |
06/29/2021 |
590.00 |
12400.00 |
07/27/2032 |
Single Source Drug |
None |
1 |
Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12 |
01/01/2021 |
49.71 |
678.89 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24 |
01/01/2021 |
99.41 |
1357.81 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649040130 |
ANUSOl-HC® (Hydrocortisone Cream, USP) 2.5%, 30gm |
01/01/2021 |
11.16 |
152.47 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649024141 |
AZASAN® (Azathioprine Tablets, USP) 100mg, 100ct |
01/01/2021 |
62.61 |
855.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649023141 |
AZASAN® (Azathioprine Tablets, USP) 75mg, 100ct |
01/01/2021 |
140.42 |
1917.88 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649020175 |
MOVIPREP® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit |
01/01/2021 |
6.72 |
118.75 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055102 |
RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
01/01/2021 |
9.85 |
134.52 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055103 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
01/01/2021 |
68.94 |
941.59 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055107 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
01/01/2021 |
9.85 |
134.52 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649055204 |
RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
01/01/2021 |
68.94 |
941.59 |
12/30/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649015090 |
RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct |
01/01/2021 |
147.74 |
2017.75 |
03/10/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649065103 |
UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
01/01/2021 |
39.91 |
705.09 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030103 |
XIFAXAN® (rifaximin) 200mg Tablets, 30ct |
01/01/2021 |
52.96 |
723.32 |
07/24/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/01/2021 |
201.89 |
2757.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2021 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
01/01/2021 |
201.89 |
2757.48 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014410 |
BRIMONIDINE TAR 0.15% 10ML |
01/20/2021 |
26.35 |
306.62 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014415 |
BRIMONIDINE TAR 0.15% 15ML |
01/20/2021 |
39.52 |
459.95 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000027 |
Sandoz Inc. |
03/31/2021 |
61314014405 |
BRIMONIDINE TAR 0.15% 5ML |
01/20/2021 |
13.18 |
153.35 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
Market conditions and dynamics |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Sandoz is engaged with CMS in ongoing discussions on the Drug Source Type for this product. Acquisition information is not applicable; Sandoz Inc. did not acquire the product within the previous five years. All information is provided by Sandoz Inc. to the best of our knowledge at the time of submission. Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.’s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.’s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. |
| Rx0000092 |
Santarus, Inc. |
03/31/2021 |
68012025820 |
CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
01/01/2021 |
70.24 |
959.30 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2021 |
70257012611 |
VARIZIG, single dose vial of 125 IU in 1.2mL (inner vial) |
02/01/2021 |
88.40 |
1892.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
None |
1306.34 |
1185.00 |
2012 |
682.50 |
None |
NDC is a non-saleable unit.
Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid. Patent Exp. Date: N/A (Biologic status) |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2021 |
70257012651 |
VARIZIG, single dose vial of 125 IU in 1.2mL (outer carton) |
02/01/2021 |
88.40 |
1892.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc. |
None |
1 |
None |
1306.34 |
1185.00 |
2012 |
682.50 |
None |
Varizig introduced to the market in 2012 as lyophilized powder. Current formulation is liquid. Patent Exp. Date: N/A (Biologic status) |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
01/01/2021 |
335.00 |
8927.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
09/30/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
07/01/2021 |
348.00 |
9275.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
12/31/2021 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
12/30/2021 |
425.00 |
9700.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
04/25/2021 |
1348.04 |
14964.65 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2021 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
11/16/2021 |
1481.50 |
16446.15 |
01/10/2032 |
Single Source Drug |
328 |
None |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
04/25/2021 |
1348.04 |
14964.65 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2021 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
11/16/2021 |
1481.50 |
16446.15 |
01/10/2032 |
Single Source Drug |
1570 |
None |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065006 |
Farydak 10 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065006 |
Farydak 10 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065106 |
Farydak 15 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065106 |
Farydak 15 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2021 |
00078065206 |
Farydak 20 mg oral capsule, 6 capsules per package |
02/01/2021 |
1058.03 |
11745.21 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
06/30/2021 |
00078065206 |
Farydak 20 mg oral capsule, 6 capsules per package |
04/25/2021 |
2337.30 |
14082.51 |
06/13/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
03/01/2019 |
Novartis |
None |
1 |
None |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
None |
| Rx0000179 |
Slayback Pharma LLC |
06/30/2021 |
71225013001 |
Norethindrone acetate,ethyl estradiol cap and ferrous fumarate cap 1mg/20mcg |
05/18/2021 |
62.22 |
180.00 |
None |
Innovator Multiple Source Drug |
966 |
None |
Price was revised due to the market dynamics. |
None |
Price was revised due to the market dynamics. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000149 |
Strongbridge Biopharma plc |
03/31/2021 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
01/18/2021 |
2046.17 |
22714.54 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000149 |
Strongbridge Biopharma plc |
09/30/2021 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
09/17/2021 |
2248.74 |
24963.28 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
12/31/2021 |
47335017795 |
ILUMYA Subcutaneous Solution Prefilled Syringe100 MG/ML PFS |
11/02/2021 |
1572.40 |
15487.40 |
02/17/2031 |
Single Source Drug |
22870 |
None |
Increased cost of production & distribution
Increased sales & marketing expenses
Competitive pressure |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
06/30/2021 |
47335030383 |
Odomzo Sonidegib Cap 200mg 30ct |
04/01/2021 |
593.43 |
12462.02 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505000405 |
Apokyn Subcutaneous Solution 5 Cartridge 30 MG/3ML |
09/09/2021 |
461.56 |
6231.06 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
5500.00 |
5290.00 |
2011 |
846.00 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505000401 |
Apokyn Subcutaneous Solution Single Cartridge 30 MG/3ML |
09/09/2021 |
92.31 |
1246.21 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
1100.00 |
1058.00 |
2011 |
169.20 |
None |
NDC 27505000401 is the inner level of a multi-level package. As such it is not listed separately on the FDA NDC Directory, it is instead included in the package description of NDC 2705000405. Supernus only markets the 27505000405 NDC. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012101 |
Oxtellar XR 150mg X 100, capsule |
01/01/2021 |
42.91 |
758.10 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012201 |
Oxtellar XR 300mg X 100, capsule |
01/01/2021 |
59.62 |
1053.21 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772012301 |
Oxtellar XR 600mg X 100, capsule |
01/01/2021 |
109.15 |
1928.32 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010330 |
Trokendi XR 100mg X 30, capsule |
01/01/2021 |
47.96 |
847.32 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010301 |
Trokendi XR 100mg X100, capsule |
01/01/2021 |
159.87 |
2824.42 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010430 |
Trokendi XR 200mg X 30, capsule |
01/01/2021 |
65.61 |
1159.09 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010401 |
Trokendi XR 200mg X100, capsule |
01/01/2021 |
218.69 |
3863.60 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010130 |
Trokendi XR 25mg X 30, capsule |
01/01/2021 |
18.58 |
328.31 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010101 |
Trokendi XR 25mg X100, capsule |
01/01/2021 |
61.90 |
1094.38 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010230 |
Trokendi XR 50mg X 30, capsule |
01/01/2021 |
24.21 |
427.65 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2021 |
17772010201 |
Trokendi XR 50mg X100, capsule |
01/01/2021 |
80.69 |
1425.54 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505011130 |
XADAGO TAB, 100MG 30CT |
09/09/2021 |
63.32 |
967.88 |
03/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
09/30/2021 |
27505011030 |
XADAGO TAB, 50MG 30CT |
09/09/2021 |
63.32 |
967.88 |
03/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available. |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000105 |
Takeda Pharmaceuticals America, Inc. |
06/30/2021 |
64764030020 |
Entyvio 300mg 20mL Vial |
04/01/2021 |
279.87 |
7276.63 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/ |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072010 |
PRIALT Intrathecal Solution 100mcg/1mL, 1ML Vial, Qty 1 |
01/04/2021 |
53.04 |
936.99 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
744.98 |
716.05 |
2004 |
608.33 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072010 |
PRIALT Intrathecal Solution 100mcg/1mL, 1ML Vial, Qty 1 |
07/01/2021 |
56.22 |
993.21 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
744.98 |
716.05 |
2004 |
608.33 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072310 |
PRIALT Intrathecal Solution 500mcg/20mL, 20ML Vial, Qty 1 |
01/04/2021 |
174.30 |
4531.80 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 10/09/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072310 |
PRIALT Intrathecal Solution 500mcg/20mL, 20ML Vial, Qty 1 |
07/01/2021 |
181.27 |
4713.07 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
03/31/2021 |
70720072210 |
PRIALT Intrathecal Solution 500mcg/5mL, 5ML Vial, Qty 1 |
01/04/2021 |
174.30 |
4531.80 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC. |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720072210 |
PRIALT Intrathecal Solution 500mcg/5mL, 5ML Vial, Qty 1 |
07/01/2021 |
181.27 |
4713.07 |
10/01/2024 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
09/27/2018 |
Jazz Pharmaceuticals, Inc. |
80000000 |
None |
Jazz Pharmaceuticals Inc. sold Prialt to TerSera Therapeutics LLC |
3724.90 |
3580.25 |
2004 |
3041.67 |
None |
TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available |
| Rx0000232 |
TerSera Therapeutics LLC |
06/30/2021 |
70183012584 |
XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets |
04/01/2021 |
353.21 |
7561.55 |
02/27/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/08/2020 |
Lexicon Pharmaceuticals, Inc |
160000000 |
None |
Lexicon received approximately $160M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer. |
6559.00 |
5961.00 |
2017 |
5164.00 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000232 |
TerSera Therapeutics LLC |
09/30/2021 |
70720095036 |
ZOLADEX (Goserelin Acetate), Implant, 3.6mg, 1 Syringe |
07/01/2021 |
48.87 |
747.01 |
04/13/2022 |
Single Source Drug |
None |
1 |
TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates. |
None |
None |
1 |
04/06/2018 |
AztraZeneca |
320000000 |
None |
AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones |
605.00 |
550.50 |
2003 |
375.99 |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017260 |
AUSTEDO TABLETS 12MG 60 |
01/01/2021 |
342.33 |
6144.53 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017060 |
AUSTEDO TABLETS 6MG 60 |
01/01/2021 |
228.20 |
4096.30 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546017160 |
AUSTEDO TABLETS 9MG 60 |
01/01/2021 |
256.70 |
4608.30 |
03/07/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546014256 |
AZILECT TABLETS 0.5MG 30 |
01/01/2021 |
78.30 |
910.90 |
08/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000217 |
Teva Neuroscience, Inc. |
03/31/2021 |
68546022956 |
AZILECT TABLETS 1MG 30 |
01/01/2021 |
78.30 |
910.90 |
08/27/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051230 |
ACTIQ BKU 1200MCG 1CTNX30 US |
01/01/2021 |
491.40 |
5718.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051201 |
ACTIQ BKU 1200MCG 1CTNX30 US IP |
01/01/2021 |
16.40 |
190.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0512-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051630 |
ACTIQ BKU 1600MCG 1CTNX30 US |
01/01/2021 |
606.20 |
7054.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459051601 |
ACTIQ BKU 1600MCG 1CTNX30 US IP |
01/01/2021 |
20.20 |
235.16 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0516-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050230 |
ACTIQ BKU 200MCG 1CTNX30 US |
01/01/2021 |
205.90 |
2396.30 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050201 |
ACTIQ BKU 200MCG 1CTNX30 US IP |
01/01/2021 |
6.90 |
79.88 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0502-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050430 |
ACTIQ BKU 400MCG 1CTNX30 US |
01/01/2021 |
260.60 |
3032.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050401 |
ACTIQ BKU 400MCG 1CTNX30 US IP |
01/01/2021 |
8.70 |
101.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0504-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050630 |
ACTIQ BKU 600MCG 1CTNX30 US |
01/01/2021 |
319.40 |
3717.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050601 |
ACTIQ BKU 600MCG 1CTNX30 US IP |
01/01/2021 |
10.60 |
123.90 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0506-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050830 |
ACTIQ BKU 800MCG 1CTNX30 US |
01/01/2021 |
378.00 |
4399.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459050801 |
ACTIQ BKU 800MCG 1CTNX30 US IP |
01/01/2021 |
12.60 |
146.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0508-30, which has separately been reported above/below. Because the multi-pack container is comprised of thirty single packs, and so the WAC numbers reported here for the single pack are 1/30th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011001 |
ADDERALL(R) TABLETS 10MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011201 |
ADDERALL(R) TABLETS 12.5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011501 |
ADDERALL(R) TABLETS 15MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844012001 |
ADDERALL(R) TABLETS 20MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844013001 |
ADDERALL(R) TABLETS 30MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844010501 |
ADDERALL(R) TABLETS 5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
57844011701 |
ADDERALL(R) TABLETS 7.5MG 100 |
01/01/2021 |
70.37 |
818.97 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459070060 |
AMRIX CAP 15 MG 1BT X60 |
01/01/2021 |
238.30 |
2773.80 |
02/26/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459070160 |
AMRIX CAP 30 MG 1BTLX60 |
01/01/2021 |
238.30 |
2773.80 |
02/26/2025 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054128 |
FENTORA TB 100MCG 1CTNX28 US |
01/01/2021 |
150.70 |
1754.00 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054104 |
FENTORA TB 100MCG 1CTNX28 US IP |
01/01/2021 |
5.40 |
62.64 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0541-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054228 |
FENTORA TB 200MCG 1CTNX28 US |
01/01/2021 |
190.40 |
2216.10 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054204 |
FENTORA TB 200MCG 1CTNX28 US IP |
01/01/2021 |
6.80 |
79.15 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0542-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054428 |
FENTORA TB 400MCG 1CTNX28 US |
01/01/2021 |
276.30 |
3215.50 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054404 |
FENTORA TB 400MCG 1CTNX28 US IP |
01/01/2021 |
9.90 |
114.84 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0544-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054628 |
FENTORA TB 600MCG 1CTNX28 US |
01/01/2021 |
358.70 |
4174.60 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054604 |
FENTORA TB 600MCG 1CTNX28 US IP |
01/01/2021 |
12.80 |
149.09 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0546-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenty-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054828 |
FENTORA TB 800MCG 1CTNX28 US |
01/01/2021 |
441.90 |
5143.00 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459054804 |
FENTORA TB 800MCG 1CTNX28 US IP |
01/01/2021 |
15.80 |
183.68 |
06/15/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 63459-0548-28, which has separately been reported above/below. Because the multi-pack container is comprised of twenthy-eight single packs, and so the WAC numbers reported here for the single pack are 1/28th of the multi-pack’s WAC numbers. The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
52544008001 |
FIORICET 50/300/40MG CAPSULES 100 |
01/01/2021 |
51.20 |
596.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
None |
Teva acquired this particular product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price; as a result, there was no one particular price that Teva paid to acquire the rights to this product. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the rights to this product in particular. |
449.93 |
None |
2013 |
227.00 |
None |
No patent expiration date listed - no patents ever listed |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
52544008201 |
FIORICET/CODEINE 50/300/40/30MG CAPS 100 |
01/01/2021 |
107.20 |
1247.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/02/2016 |
Watson/Actavis |
None |
None |
Teva acquired this particular product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price; as a result, there was no one particular price that Teva paid to acquire the rights to this product. We were, nonetheless, required to enter a non-zero value in the "Acquisition Price" field, and so we entered $33,430,000,000, which is the total amount that Teva paid (along with roughly 100 million shares of Teva stock) in connection with the broader deal referenced above. Once again, and to be clear, this total is not representative of the amount that Teva paid for the rights to this product in particular. |
942.09 |
None |
2013 |
475.00 |
None |
No patent expiration date listed - no patents ever listed |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459041230 |
GABITRIL TAB 12MG 1BTLX30 |
01/01/2021 |
36.30 |
422.20 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459041630 |
GABITRIL TAB 16MG 1BTLX30 |
01/01/2021 |
47.50 |
552.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459040230 |
GABITRIL TAB 2MG 1BTLX30 |
01/01/2021 |
28.10 |
326.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459040430 |
GABITRIL TAB 4MG 1BTLX30 |
01/01/2021 |
28.10 |
326.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459021530 |
NUVIGIL TAB 150MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459022030 |
NUVIGIL TAB 200MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459022530 |
NUVIGIL TAB 250MG 1BTLX30 |
01/01/2021 |
79.60 |
926.40 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459020530 |
NUVIGIL TAB 50MG 1BTLX30 |
01/01/2021 |
26.50 |
307.90 |
06/18/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459010130 |
PROVIGIL TAB 100MG 1BTLX30 |
01/01/2021 |
111.40 |
1296.40 |
05/29/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000019 |
Teva Pharmaceuticals USA |
03/31/2021 |
63459020130 |
PROVIGIL TAB 200MG 1BTLX30 |
01/01/2021 |
168.30 |
1958.80 |
05/29/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000218 |
Teva Respiratory, LLC |
06/30/2021 |
59310057922 |
PROAIR INH AERO 90MCG 1INH 200 |
06/01/2021 |
3.95 |
70.83 |
01/01/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
06/30/2021 |
59310058020 |
PROAIR RESPICLICK 200 DOSE-117 |
06/01/2021 |
3.69 |
66.21 |
01/13/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank; Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310040606 |
QNASL PLV INHALER 40MCG 60/ACT TRADE |
01/01/2021 |
14.35 |
257.52 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310041012 |
QNASL PLV INHALER 80MCG 120/ACT TRADE |
01/01/2021 |
14.35 |
257.52 |
10/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310030240 |
QVAR BA INHALER 40MCG 120/ACT |
01/01/2021 |
9.51 |
199.72 |
01/25/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000218 |
Teva Respiratory, LLC |
03/31/2021 |
59310030480 |
QVAR BA INHALER 80MCG 120/ACT |
01/01/2021 |
12.73 |
267.41 |
01/25/2039 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285052302 |
ANTABUSE TABLETS 250MG 100 |
01/01/2021 |
82.40 |
959.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285052402 |
ANTABUSE TABLETS 500MG 100 |
01/01/2021 |
131.90 |
1535.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285042410 |
AYGESTIN(R) TABLETS 5MG 50 |
01/01/2021 |
23.80 |
277.20 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285013197 |
LOESTRIN (R) 21 TABLETS 1.0MG/20MCG 105 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012797 |
LOESTRIN (R) 21 TABLETS 1.5MG/30MCG 105 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012570 |
LOESTRIN (R) FE 28 TAB 1MG/20MCG 140 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012870 |
LOESTRIN (R) FE 28 TABLETS 1.5MG/30MCG 140 |
01/01/2021 |
66.10 |
769.70 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
No patent expiration date listed - no patents ever listed
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285009287 |
LOSEASONIQUE™ TAB 182 |
01/01/2021 |
76.90 |
895.10 |
12/05/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285012058 |
MIRCETTE 28 TABLETS .15MG/.02MG .01MG |
01/01/2021 |
82.90 |
964.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285006390 |
PREFEST(R) TABLETS 180 |
01/01/2021 |
84.40 |
982.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285043187 |
QUARTETTE (TM) TAB 182 |
01/01/2021 |
92.10 |
1071.90 |
03/11/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285043165 |
QUARTETTE (TM) TAB 91 |
01/01/2021 |
46.10 |
535.95 |
03/11/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC listed is for a single pack. In fact, however, Teva does not sell this product as a single pack. Instead, the product is sold in a multiple-pack container. The NDC for that container is 51285-0431-87, which has separately been reported above/below. Because the multi-pack container is comprised of two single packs, the WAC numbers reported here for the single pack are half of the multi-pack’s WAC numbers. Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285008787 |
SEASONIQUE(TM) TAB 182 |
01/01/2021 |
76.90 |
895.10 |
12/05/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Teva developed and launched the product. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285004001 |
ZIAC(R) TABLETS 10MG/6.25MG 30 |
01/01/2021 |
19.40 |
225.80 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285004702 |
ZIAC(R) TABLETS 2.5MG/6.25MG 100 |
01/01/2021 |
64.70 |
752.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000219 |
Teva Women's Health, Inc. |
03/31/2021 |
51285005002 |
ZIAC(R) TABLETS 5MG/6.25MG 100 |
01/01/2021 |
64.70 |
752.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The drug was not acquired within the last 5 years. |
| Rx0000183 |
Tris Pharma, Inc |
03/31/2021 |
27808010201 |
Dyanavel XR 2.5mg/mL Extended-Release Suspension |
01/04/2021 |
73.66 |
1303.45 |
None |
Single Source Drug |
None |
1 |
Increased operational costs. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000090 |
UCB, Inc |
03/31/2021 |
50474070062 |
CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS |
01/01/2021 |
185.21 |
4815.56 |
02/13/2024 |
Single Source Drug |
1338360000 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2021 |
50474071079 |
CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2021 |
185.21 |
4815.56 |
02/13/2024 |
Single Source Drug |
1338360000 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000090 |
UCB, Inc |
03/31/2021 |
50474071081 |
CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES |
01/01/2021 |
555.64 |
14446.68 |
02/13/2024 |
Single Source Drug |
1338360000 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. |
| Rx0000036 |
United Therapeutics |
12/31/2021 |
66302020604 |
Tyvaso (treprostinil) inhalation solution, Tyvaso Institutional Starter Kit (ISK) 1 BOX in 1 KIT > 4 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE |
10/01/2021 |
229.33 |
4909.49 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Price decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
12/31/2021 |
66302020602 |
Tyvaso (treprostinil) inhalation solution, Tyvaso Patient Resupply Kit (RSK) 1 BOX in 1 KIT > 28 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE |
10/01/2021 |
887.45 |
18998.67 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Price decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
12/31/2021 |
66302020601 |
Tyvaso (treprostinil) inhalation solution, Tyvaso Patient Starter Kit (PSK) 1 BOX in 1 KIT > 28 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE |
10/01/2021 |
990.00 |
21194.08 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Price decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
12/31/2021 |
66302020603 |
Tyvaso (treprostinil) inhalation solution,Tyvaso Supplemental Refill 4 ct 4 AMPULE in 1 BOX > 2.9 mL in 1 AMPULE |
10/01/2021 |
126.78 |
2714.09 |
05/14/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Price decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain. |
| Rx0000036 |
United Therapeutics |
03/31/2021 |
66302001401 |
Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial |
01/13/2021 |
1176.20 |
13056.96 |
03/01/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Unit sales data- This information is confidential and proprietary, and not publicly available or within the public domain.
Cost increase factors- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Change/Improvement description- This information was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.
Acquisition fields have not been completed because the product was not acquired from another manufacturer within the last 5 years |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068010102 |
FANAPT® (iloperidone) 1 MG Oral Tablet; bottles of 60 |
01/20/2021 |
110.85 |
1496.53 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068010102 |
FANAPT® (iloperidone) 1 MG Oral Tablet; bottles of 60 |
08/01/2021 |
119.72 |
1616.25 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068011002 |
FANAPT® (iloperidone) 10 MG Oral Tablet; bottles of 60 |
01/20/2021 |
218.44 |
2948.90 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068011002 |
FANAPT® (iloperidone) 10 MG Oral Tablet; bottles of 60 |
08/01/2021 |
235.91 |
3184.81 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068011202 |
FANAPT® (iloperidone) 12 MG Oral Tablet; bottles of 60 |
01/20/2021 |
218.44 |
2948.90 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068011202 |
FANAPT® (iloperidone) 12 MG Oral Tablet; bottles of 60 |
08/01/2021 |
235.91 |
3184.81 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068010202 |
FANAPT® (iloperidone) 2 MG Oral Tablet; bottles of 60 |
01/20/2021 |
110.85 |
1496.53 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068010202 |
FANAPT® (iloperidone) 2 MG Oral Tablet; bottles of 60 |
08/01/2021 |
119.72 |
1616.25 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068010402 |
FANAPT® (iloperidone) 4 MG Oral Tablet; bottles of 60 |
01/20/2021 |
110.85 |
1496.53 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068010402 |
FANAPT® (iloperidone) 4 MG Oral Tablet; bottles of 60 |
08/01/2021 |
119.72 |
1616.25 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068010602 |
FANAPT® (iloperidone) 6 MG Oral Tablet; bottles of 60 |
01/20/2021 |
136.40 |
1841.39 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068010602 |
FANAPT® (iloperidone) 6 MG Oral Tablet; bottles of 60 |
08/01/2021 |
147.31 |
1988.70 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068010802 |
FANAPT® (iloperidone) 8 MG Oral Tablet; bottles of 60 |
01/20/2021 |
136.40 |
1841.39 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068010802 |
FANAPT® (iloperidone) 8 MG Oral Tablet; bottles of 60 |
08/01/2021 |
147.31 |
1988.70 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068011304 |
FANAPT® (iloperidone) Titration Pack (2x1mg, 2x2mg, 2x4mg, 2x6mg) Total 8 Oral Tablets |
01/20/2021 |
14.78 |
199.56 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068011304 |
FANAPT® (iloperidone) Titration Pack (2x1mg, 2x2mg, 2x4mg, 2x6mg) Total 8 Oral Tablets |
08/01/2021 |
15.96 |
215.52 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2021 |
43068022001 |
HETLIOZ® (tasimelteon) 20 MG Oral Tablet; bottles of 30 |
01/20/2021 |
1491.25 |
20131.89 |
08/29/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000098 |
Vanda Pharmaceuticals Inc. |
09/30/2021 |
43068022001 |
HETLIOZ® (tasimelteon) 20 MG Oral Tablet; bottles of 30 |
08/01/2021 |
1811.87 |
21943.76 |
08/29/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992307501 |
Envarsus XR .75mg 100 Tab |
12/17/2021 |
15.02 |
444.23 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992307503 |
Envarsus XR .75mg 30 Tab |
12/17/2021 |
4.51 |
133.28 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992301001 |
Envarsus XR 1mg 100 Tab |
12/17/2021 |
20.03 |
592.32 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992301003 |
Envarsus XR 1mg 30 Tab |
12/17/2021 |
6.01 |
177.70 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992304001 |
Envarsus XR 4mg 100 Tab |
12/17/2021 |
80.12 |
2369.24 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000416 |
Veloxis Pharmaceuticals, Inc. |
12/31/2021 |
68992304003 |
Envarsus XR 4mg 30 Tab |
12/17/2021 |
24.04 |
710.76 |
08/30/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025007130 |
Conzip 100 MG capsule 30 CT |
01/01/2021 |
27.35 |
369.17 |
04/11/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025007230 |
Conzip 200 MG capsule 30 CT |
01/01/2021 |
35.84 |
483.80 |
04/11/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025007330 |
Conzip 300 MG capsule 30 CT |
01/01/2021 |
49.57 |
669.19 |
04/11/2022 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025006030 |
Corvite FE 0.1 MG tablet 30 CT |
01/01/2021 |
10.35 |
183.72 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025005230 |
Corvite FE 150 1MG tablet 30 CT |
01/01/2021 |
10.35 |
139.67 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025006530 |
Divigel Transdermal Gel 0.25MG/0.25GM 30 |
01/01/2021 |
7.14 |
150.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025006630 |
Divigel Transdermal Gel 0.5MG/0.5GM 30 |
01/01/2021 |
7.14 |
150.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025008330 |
Divigel Transdermal Gel 0.75MG/0.75GM 30 |
01/01/2021 |
7.14 |
150.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025008630 |
Divigel Transdermal Gel 1.25MG/GM 30 |
01/01/2021 |
7.14 |
150.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025006730 |
Divigel Transdermal Gel 1MG/GM 30 |
01/01/2021 |
7.14 |
150.03 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025004610 |
Lorzone Oral Tablet 375MG 100 CT |
01/01/2021 |
72.71 |
981.57 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025004710 |
Lorzone Oral Tablet 750MG 100 CT |
01/01/2021 |
81.30 |
1097.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not aquired within the last 5 years |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025004960 |
OB Complete DHA 1 softgel 60 CT |
01/01/2021 |
14.12 |
190.62 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025004430 |
OB Complete One 1 softgel 30 CT |
01/01/2021 |
14.37 |
194.04 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025005930 |
OB Complete Petite 1 softgel 30 CT |
01/01/2021 |
13.93 |
188.11 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025004330 |
OB Complete Premier 1 tablet 30 CT |
01/01/2021 |
14.37 |
135.99 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000155 |
Vertical Pharmaceuticals, LLC |
03/31/2021 |
68025001010 |
OB Complete Prenatal 1 caplet 100 CT |
01/01/2021 |
17.96 |
242.47 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Developed by Vertical |
| Rx0000314 |
VistaPharm Inc |
06/30/2021 |
66689006310 |
Donnatal elixer 5mL in 10 UD cups per case |
04/12/2021 |
33.00 |
378.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500011001 |
Lazanda® 100 mcg (fentanyl nasal spray) CII, 1 bottle (contains 8 metered dose sprays) |
12/01/2021 |
84.12 |
1018.82 |
01/26/2032 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
11/01/2018 |
Assertio Therapeutics |
None |
1 |
No comment. |
752.57 |
665.74 |
2013 |
302.48 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500014001 |
Lazanda® 400 mcg (fentanyl nasal spray) CII, 1 bottle (contains 8 metered dose sprays) |
12/01/2021 |
134.15 |
1624.65 |
01/26/2032 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
11/01/2018 |
Assertio Therapeutics |
None |
1 |
No comment. |
1100.08 |
1061.60 |
2013 |
432.48 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500000110 |
Subsys®™ 100 mcg (fentanyl sublingual spray) CII, 10 units / carton |
12/01/2021 |
63.26 |
766.31 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
644.99 |
589.00 |
2014 |
309.99 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500001215 |
Subsys®™ 1200 mcg (fentanyl sublingual spray) CII – 2 x 600 mcg, 30 units / carton |
12/01/2021 |
504.92 |
6115.91 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
5147.64 |
4701.00 |
2014 |
2213.70 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500001615 |
Subsys®™ 1600 mcg (fentanyl sublingual spray) CII – 2 x 800 mcg, 30 units / carton |
12/01/2021 |
631.01 |
7642.22 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
6432.30 |
5874.30 |
2014 |
2727.00 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500000230 |
Subsys®™ 200 mcg (fentanyl sublingual spray) CII, 30 units / carton |
12/01/2021 |
250.64 |
3034.39 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
2553.98 |
2332.50 |
2014 |
1174.50 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500000430 |
Subsys®™ 400 mcg (fentanyl sublingual spray) CII, 30 units / carton |
12/01/2021 |
379.91 |
4600.17 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
3871.87 |
3536.10 |
2014 |
1704.90 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
71500000630 |
Subsys®™ 600 mcg (fentanyl sublingual spray) CII, 30 units / carton |
12/01/2021 |
504.92 |
6115.91 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
5147.64 |
4701.00 |
2014 |
2213.70 |
None |
None |
| Rx0000065 |
West Therapeutic Development, LLC |
12/31/2021 |
20482000830 |
Subsys®™ 800 mcg (fentanyl sublingual spray) CII, 30 units / carton |
12/01/2021 |
631.01 |
7642.22 |
04/27/2030 |
Single Source Drug |
None |
1 |
Market Conditions and increase in REM fees |
None |
NA |
None |
09/26/2019 |
Insys Therapeutics |
None |
1 |
No comment. |
6432.30 |
5874.30 |
2014 |
2904.39 |
None |
None |
| Rx0000163 |
Zyla Life Sciences |
06/30/2021 |
69344011311 |
OXAYDO (Oxycodone HCL Tablet) 5 MG 100 CT BOTTLE |
04/01/2021 |
79.90 |
886.94 |
03/16/2025 |
Single Source Drug |
3037 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years.
Comment re Year Introduced and WAC at Introduction: This product was acquired over 5 years ago, and despite utilizing reasonable efforts, certain historical data is unavailable to Assertio. The FDA Approval Date per the Orange Book is provided as Year Drug Introduced to Market (2011) and the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) is provided as WAC at Introduction of $425.00. |
| Rx0000163 |
Zyla Life Sciences |
06/30/2021 |
69344021311 |
OXAYDO (Oxycodone HCL Tablet) 7.5 MG 100 CT BOTTLE |
04/01/2021 |
119.71 |
1328.95 |
03/16/2025 |
Single Source Drug |
7773 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years.
Comment re Year Introduced and WAC at Introduction: This product was acquired over 5 years ago, and despite utilizing reasonable efforts, certain historical data is unavailable to Assertio. The FDA Approval Date per the Orange Book is provided as Year Drug Introduced to Market (2011) and the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 9/11/2015) is provided as WAC at Introduction of $638.00. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2021 |
69344014463 |
Sprix 15.75mg/1 Spray, Metered (1 Bottle) |
01/01/2021 |
27.49 |
420.19 |
None |
Innovator Multiple Source Drug |
None |
1 |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see statement on cost increase factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years.
Comment on data element #8: While this is an active NDC in the compendia, we did not have any sales of the single unit NDC. We attempted to put 0 in this field but the validation failed so based on guidance from CA we are indicating non-public in data element #9. There were no US Sales of this NDC in 2020. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2021 |
69344014443 |
Sprix 15.75mg/1 Spray, Metered (5 Bottles per Carton) |
01/01/2021 |
137.45 |
2100.97 |
None |
Innovator Multiple Source Drug |
36312 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see statement on cost increase factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This drug was not acquired in the past five years. |
| Rx0000163 |
Zyla Life Sciences |
03/31/2021 |
69344010233 |
Suppository Indocin 50mg per suppository (30 Suppository/Box) |
01/01/2021 |
554.89 |
6159.79 |
None |
Non-innovator Multiple Source Drug |
12432 |
None |
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. |
None |
None - see statement on cost increase factors |
None |
01/31/2019 |
Iroko Pharmaceuticals, Inc. |
87000000 |
None |
What Zyla US Inc. has provided in Field #16 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M:
- Significant ongoing royalty payments on net sales
- Additional debt burden of $55M and royalty payments associated with this debt
- Cost of acquired inventory
- Bankruptcy restructuring costs in connection with acquisition
- Assumption of additional liabilities in connection with acquisition
- Post-marketing and development costs
- Commercial infrastructure costs
- Intellectual Property litigation and maintenance costs
- Costs to comply with regulatory requirements
- Co-payment assistance program utilization costs
- Significant increase in manufacturing costs |
2550.00 |
2550.00 |
1984 |
309.62 |
None |
Comment on data elements #21 and #22: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant to do so) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore: Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market for #21 and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013) for #22. |